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1. Summary 
 
Organic anion transporting polypeptides (called OATPs in humans and Oatps in 
other species) are members of the SLCO (solute carrier organic anion transporting 
polypeptides) gene family belonging to the SLC superfamily of transporters. They 
represent a group of putative 12 transmembrane domain (TMD) transport proteins 
embedded in the plasma membrane where they are responsible for the cellular 
uptake of a broad range of substances independently from ATP and Na+, Cl-, or K+ 
gradients.  
OATPs/Oatps have been described in several species including human, mouse, rat, 
cow, horse, quail, skate, and dog. To date, 11 members of the OATP family have 
been identified in humans. Multi-substrate specificity and broad tissue distribution are 
common characteristics of many OATPs (e.g., OATP3A1, OATP4A1, OATP2B1, and 
OATP2A1), but some OATPs, such as OATP1B1 and OATP1B3, seem to exhibit 
unique cellular expression patterns. These proteins are found on the basolateral 
membrane of human hepatocytes. OATP6A1 is another organ-specific OATP that is 
expressed exclusively in the testis. To date, no data are available concerning the 
distribution of OATP5A1 within the human body as well as substrate specifity.  
Typical endogenous OATP substrates include bile acids, bilirubin, steroid conjugates, 
thyroid hormones, eicosanoids, and oligopeptides. In addition, a wide range of 
exogenous substances serve as OATP substrates, including antibiotics, statins, 
fexofenadine, and glibenclamide, as well as cytotoxic anticancer agents such as 
methotrexate, paclitaxel, docetaxel, and the small targeted inhibitor imatinib. 
Nevertheless, only a few OATPs have been thoroughly characterized with regard to 
their substrate specificity. For instance, the substrates for OATP5A1 and OATP6A1 
are currently completely unknown.  
The aim of this thesis was to investigate the possible role of OATPs present in 
cancer tissues.  
To this end, the expression and distribution of OATPs in malignant tissues, as well as 
non-malignant tissues, deriving from breast, bone, liver and ovarian cancers were 
studied. Furthermore, uptake studies using radiolabeled paclitaxel as a substrate 
were performed on ovarian cancer cell lines and on cRNA microinjected X. laevis 
oocytes in order to elucidate the active transporters of this taxane among the OATP 
family members. In the cancer cell lines, expression of OATPs was assessed with 
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respect to paclitaxel transport. Finally, these findings could have a profound impact 
on the use of taxane-based chemotherapy regimens.  
Ovarian cancer, also known as the “silent killer” or “the disease that whispers”, is 
usually diagnosed at an advanced stage because early symptoms are inconspicuous 
and reliable diagnostic biomarkers are not available. As a result, it is the most lethal 
of all the gynecologic malignancies and paclitaxel represents an important first-line 
anticancer agent in the treatment of ovarian cancer.  
By systematically investigating the transport properties of paclitaxel for all 11 OATPs 
using cRNA microinjected X. laevis oocytes, OATP1B1 was identified as an 
additional uptake transporter for paclitaxel. Paclitaxel uptake followed Michaelis-
Menten saturation kinetics with a Km value of 0.6 µM, while OATP1B3 displayed a Km 
of 1.6 µM, which indicates that 1B1 has a higher affinity than 1B3 for this taxane. 
Moreover, upon exposing OATP5A1 and OATP6A1 cRNA-injected X. laevis oocytes 
to the prototypical OATP substrate estrone-3-sulfate (E3S), only OATP5A1-mediated 
transport of E3S was observed. Thus, OATP1B1 was found to be a novel, high-
affinity and active paclitaxel transporter in transfected X. laevis oocytes and the same 
may be true for the uptake of this compound in human liver and ovarian cancer cells.   
Assessment of the mRNA expression profile by TaqMan® real-time RT-PCR in the 
ovarian cancer cell lines OVCAR-3 and SK-OV-3 revealed a higher expression of the 
paclitaxel transporting OATP1B3 and other OATPs, including OATP1B1 in the SK-
OV-3 cells. Indeed, higher initial uptake rates for this taxane were also measured in 
the SK-OV-3 cells than in the OVCAR-3 cells. In a subsequent study, the mRNA 
expression profile of the 11 OATPs and of the ABC transporters, which were 
previously associated with drug resistance in ovarian carcinomas, was assessed in a 
panel of 191 clinically defined ovarian cancer patients (treatment, response to 
chemotherapy, disease-free survival, and overall survival) by TaqMan® real-time RT-
PCR. It is important to note that of all the OATPs, only OATP3A1 expression was 
shown to be significantly correlated with the tumor (FIGO) stage. Furthermore, by 
implementing a Cox regression model, a highly significant predictor for the disease-
free survival of ovarian cancer patients was found by combining the expression levels 
of three candidate genes, namely SLCO6A1 and two ABC-transporters, with the 
drug-efflux pump ABCC2 (MRP2) and ABCB2 (TAP1), a transporter associated with 
antigen processing. Analysis of these transporters is now being carried out on the 
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protein level using immunofluorescence staining methods and a quantitative 
evaluation of the immunostaining pattern. 
 
In subsequent studies, a comparative investigation involving malignant and adjacent 
non-malignant tissues derived from 13 breast cancer patients was performed. The 
investigation of the OATP expression at the mRNA level in the different tissues and 
cell lines was accomplished using TaqMan® real-time RT-PCR. Indeed, large 
differences in the expression of six OATPs were found between cancerous and non-
cancerous samples, with higher mRNA levels of most OATPs in the latter group. 
However, no significant correlation of the expression levels of any OATPs in non-
malignant and malignant breast tissue samples with the patient’s age, tumor size, 
hormonal receptor, or HER-2 status could be detected, possibly due to the small 
sample size. Nevertheless, OATPs might play an important role in breast cancer 
progression because at least seven OATPs are known to mediate estrone-3-sulfate 
(E3S) entry into cells. E3S is not an active steroid hormone but represents an 
important storage form, and it has been shown that hormone-dependent breast 
cancer cells are able to convert E3S to active estrogen via the steroid sulfatase 
enzyme. Moreover, OATPs might be important determinants for the efficacy of 
certain anticancer drugs. However, the known paclitaxel transporter, OATP1B3, was 
found not to be expressed in breast cancer tissue in this study. 
Similar results were obtained in a study examining the expression of all 11 OATPs in 
malignant and benign bone tumors using TaqMan® real-time RT-PCR. That study 
showed that mRNA levels of OATPs were generally reduced in the malignant 
specimens derived from osteosarcomas and bone metastases when compared to 
benign bone lesions from 21 patients. Distinct differences were also observed 
between the MG-63 and HOS bone cancer cell lines and primary bone cells (i.e., 
human osteoblast outgrowth cells and bone marrow stromal cells). OATPs can have 
diverse effects on bone and bone disease progression. Sex steroid hormones are 
important regulators of bone turnover and have effects on the activity of osteoblasts 
and osteoclasts. In addition to E3S, dehydroepiandrosterone sulfate (DHEAS) can 
also be taken up into bone cells via OATPs and be converted into active 17β-
estradiol. Moreover, the OATP substrate prostaglandin E2 (PGE2) is a potent inducer 
of osteolysis, but once it is taken up into cells, it can be rapidly inactivated via 
oxidation. Several OATPs are also involved in the transport of methotrexate, an 
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antifolate drug used in the treatment of osteosarcoma. Thus, OATPs could be an 
important influence on bone tumor growth and progression by providing important 
regulators of bone homeostasis and by influencing the efficacy of chemotherapy 
regimens in terms of the uptake of certain anticancer drugs. 
 
The liver is the most important detoxification organ and functions by removing toxic 
endogenous metabolites and xenobiotic substances from circulating blood. OATPs 
are known to play an important role in this process. Hepatocellular carcinoma (HCC) 
is currently the third most common cause of cancer-related death in the world. Thus, 
differences in OATP expression in HCC, cholangiocellular carcinoma (CCC) and 
metastases from primary tumors in the liver were compared to non-malignant 
adjacent tissues from 22 patients. The most pronounced reduction in “liver-specific” 
OATP1B1 and OATP1B3 mRNA expression was observed in CCC using TaqMan® 
real-time RT-PCR and may at least partly reflect the replacement of hepatocytes by 
malignant cells transformed from cholangiocytes and their precursors. It also became 
evident that mRNA expression of OATP2A1 and OATP5A1 is upregulated in primary 
and secondary hepatic tumors. This observation was confirmed at the protein level 
by immunofluorescence staining. Moreover, OATP4A1 upregulation was restricted to 
liver metastases, which was shown at the mRNA level as well as by protein 
immunofluorescence staining. The distinct expression pattern of individual OATPs 
suggests their specific functions in tumor cells, which may involve the transport of 
molecules important for cellular signaling and the transport of drugs used in therapy. 
 
In summary, the present results regarding the expression of various OATP 
transporters in breast cancer, bone cancer, and liver cancer, as well as ovarian 
cancer, provide the basis for further investigations into the transport processes for 
endogenous and exogenous compounds in malignant and non-malignant disease. 
These results may also be important for further investigations regarding the efficacy 
of a given treatment in cancer therapy. 
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2. Zusammenfassung 
 
“Organic Anion Transporting Polypeptides“ (beim Menschen OATPs, bei anderen 
Spezies Oatps) gehören zur Überfamilie der SLC-Transporter, worin sie die SLCO 
(Solute Carrier OATP) Genfamilie bilden. Sie repräsentieren eine Gruppe von in die 
Plasmamembran eingebetteten Transport-Proteinen mit vermutlich 12 
Transmembran-Domänen (TMD). OATPs/Oatps sind verantwortlich für die zelluläre 
Aufnahme einer breiten Palette von Stoffen, unabhängig von ATP bzw. Na+, Cl- oder 
K+ Gradienten. OATPs/Oatps wurden in mehreren Spezies, darunter Mensch, Maus, 
Ratte, Rind, Pferd, Wachteln, Rochen und Hund beschrieben. Bisher wurden beim 
Menschen elf Mitglieder der OATP-Familie identifiziert. Häufige Merkmale vieler 
OATPs sind Multisubstrat-Spezifität und eine breite Verteilung im Gewebe (zB. 
OATP3A1, OATP4A1, OATP2B1 und OATP2A1), aber einige OATPs, zB. OATP1B1 
und OATP1B3, scheinen spezifische zelluläre Expressionsmuster aufzuweisen, da 
sich beide ausschließlich auf der basolateralen Membran von Hepatozyten befinden. 
Ein weiterer organspezifischer OATP ist OATP6A1, dessen Expression 
ausschließlich im Hodengewebe gezeigt wurde. Derzeit liegen keine Daten über die 
Verteilung von OATP5A1 innerhalb des menschlichen Körpers vor. Typische 
endogene OATP Substrate bestehen aus Gallensäuren, Bilirubin, Steroid-
Konjugaten, Schilddrüsenhormonen, Eicosanoiden und Oligopeptiden. Darüber 
hinaus dienen eine Vielzahl von exogenen Substanzen als Substrate für OATPs, 
darunter auch verschiedene Medikament wie zB. Antibiotika, Statine, Fexofenadin, 
Glibenclamid, aber auch Krebsmedikamente wie die Zytostatika Methotrexat, 
Paclitaxel, Docetaxel aber auch Imatinib. Dennoch ist nur eine geringe Anzahl von 
OATPs hinsichtlich ihrer Substratspezifität gut charakterisiert, zB. sind die Substrate 
für OATP5A1 und OATP6A1 derzeit nicht bekannt. Das Ziel dieser Arbeit war es, die 
mögliche Rolle von OATPs in verschiedenen Tumorentitäten zu untersuchen. Dabei 
wurde die Expression und die Verteilung der OATPs in malignen als auch nicht-
malignen Geweben der weiblichen Brust untersucht sowie auch in Knochen-, Leber- 
und Eierstockkrebsgewebe. Darüber hinaus wurden Aufnahme-Studien mit 
Ovarialkarzinom-Zelllinien sowie mit cRNA-mikroinjizierten X. laevis Oozyten 
durchgeführt wobei radioaktiv markiertes  Paclitaxel als Substrat diente, um aktive 
Transporter dieses Taxans unter den OATP-Familienmitgliedern zu identifizieren. 
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Diese Erkenntnisse könnten schließlich wichtige Auswirkungen auf den Erfolg der 
Chemotherapie mit Taxanen haben.  
Eierstockkrebs, auch als "leiser Killer" oder "die Krankheit, die flüstert“ bekannt, wird 
in der Regel erst in einem fortgeschrittenen Stadium diagnostiziert, da frühe 
Symptome unauffällig und zuverlässige diagnostische Biomarker nicht verfügbar 
sind. Daher ist es die tödlichste aller gynäkologischen Malignomen. Paclitaxel ist ein 
wichtiges “first line“ Therapiemittel in der Behandlung dieser Krebsart. Untersuchung 
der mRNA Genexpression mittels TaqMan® real-time RT-PCR in den 
Ovarialkarzinomzelllinen OVCAR-3 und SK-OV-3 zeigte eine höhere Expression des 
Paclitaxeltransporters OATP1B3 aber auch von anderen OATPs, unter anderem 
OATP1B1 in den SK -OV-3 Zellen. In der Tat wurden auch höhere Aufnahmeraten 
für dieses Taxan in der SK-OV-3 Zelllinie, verglichen mit OVCAR-3, gemessen. 
Durch die systematische Untersuchung der Transporteigenschaften von Paclitaxel 
für alle elf OATPs mittels cRNA mikroinjizierten X. laevis Oozyten, konnte OATP1B1 
als zusätzlicher Aufnahmetransporter für Paclitaxel identifiziert werden. In der 
durchgeführten Michaelis-Menten Kinetik-Analyse, wurde für den OATP1B1-
vermittelteten Paclitaxel-Transport ein Km-Wert von 0,6 µM bzw. für OATP1B3 ein 
Km-Wert von 1,6 µM gemessen was auf eine höhere Affinität zu Paclitaxel von 
OATP1B1 im Vergleich zu OATP1B3 hinweist. Darüber hinaus  wurde mit dem 
prototypischen OATP Substrat Östron-3-Sulfat (E3S) in OATP5A1 und OATP6A1 
cRNA injizierten X. laevis Oozyten nur OATP5A1 vermittelter Transport von Estron-3-
Sulfat (E3S) beobachtet. Zusammenfassend konnte OATP1B1 als neuer hochaffiner 
Paclitaxel-Transporter in transfizierten X. laevis Oozyten bestimmt werden, und dies 
kann auch für die Aufnahme von Paclitaxel in die Leber und in Ovarialkarzinomzellen 
zutreffen. 
In einer nachfolgenden Studie wurde die mRNA Genexpression aller elf OATPs und 
verschiedener ABC-Transporter in einem Panel von 191 klinisch genau bewerteten 
Ovarialkarzinom-Patientinnen mit Hilfe von TaqMan® real-time RT-PCR bestimmt. 
Als ein erstes Ergebnis konnte OATP3A1 als einziges Kandidatengen signifikant mit 
dem Stadium der FIGO-Klassifizierung korreliert werden. Darüber hinaus wurde 
durch die Implementierung eines Cox-Regressionsmodell ein hoch signifikanter 
Prädiktor für das krankheitsfreie Überleben von Patientinnen mit Ovarialkarzinom 
durch die Kombination der Expression von drei Kandidatengenen gefunden, nämlich 
SLCO6A1 und die ABC-Transporter ABCC2 (MRP2) und ABCB2 (TAP1). TAP1 ist 
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ein Transporter, der mit Antigen-Präsentation assoziiert ist. In derzeit laufenden 
Studien werden diese Transporter auch auf der Proteinebene durch 
Immunfluoreszenzfärbung untersucht. 
In einer weiteren Studie wurde eine vergleichende Untersuchung zwischen malignen 
und nicht-malignen angrenzenden Gewebeproben von 13 Brustkrebspatientinnen 
durchgeführt. Die Analyse der OATP Expression auf mRNA-Ebene in den 
verschiedenen Geweben und Zelllinien wurde mit Hilfe von TaqMan® real-time RT-
PCR durchgeführt. Tatsächlich konnten große Unterschiede in der Expression von 
sechs OATPs zwischen Brustkrebs- und Kontroll-Gewebeproben mit höherem mRNA 
Gehalt in den nicht-malignen Proben nachgewiesen werden. Allerdings konnte keine 
signifikante Korrelation mit Patientenalter, Tumorgröße, Hormon-Rezeptor- oder 
HER-2-Status und der Expression von OATPs in nicht-malignen und malignen 
Brustgewebe Proben nachgewiesen werden, möglicherweise aufgrund der geringen 
Fallzahl. Dennoch kann davon ausgegangen werden, daß OATPs eine wichtige Rolle 
bei der Progression von Brustkrebs spielen könnten da es von mindestens sieben 
OATPs bekannt ist, E3S in Zellen zu transportieren. E3S ist kein aktives 
Steroidhormon, stellt allerdings eine wichtige Östrogen-Speicherform dar und es hat 
sich gezeigt, daß hormonabhängige Brustkrebszellen in der Lage sind über das 
Enzym Steroidsulfatase E3S in aktives Östrogen umwandeln zu können. Außerdem 
könnten OATPs wichtige Determinanten für die Wirksamkeit bestimmter 
Krebsmedikamente sein. Unter anderem wurde OATP1B3 als hochaffiner Paclitaxel-
Transporter identifiziert, ein Wirkstoff der in der Behandlung von metastasierendem 
Brustkrebs Anwendung findet. Obwohl Expression von OATP1B3 in 
Brustkrebsgewebe in dieser Studie nicht festgestellt wurde, ist es wahrscheinlich, 
daß andere OATPs an der Paclitaxel-Aufnahme beteiligt sind, bedingt durch die 
typischerweise überlappende Substratspezifität, die ein gemeinsames Merkmal der 
OATPs darstellt.  
Ähnliche Ergebnisse wurden in einer Arbeit über die Untersuchung der Expression 
von sämtlichen OATPs in gutartigen und malignen Knochentumoren mittels TaqMan® 
real-time-RT-PCR gewonnen. Dabei konnte in Übereinstimmung mit der 
vorangegangenen Arbeit gezeigt werden, daß die Expression von OATPs auf mRNA-
Ebene im Vergleich zu gutartigen Läsionen des Knochens in malignen Proben aus 
Osteosarkomen und Knochenmetastasen im Allgemeinen reduziert war. Deutliche 
Unterschiede wurden auch zwischen den Knochenkrebs-Zelllinien MG-63 und HOS 
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und primären Knochenzellen (“human osteoblast outgrowth cells“, Stromazellen des 
Knochenmarks) festgestellt. OATPs können verschiedene Auswirkungen auf den 
Knochen bzw. den Verlauf von Knochenerkrankungen haben. Sex-Steroidhormone 
sind wichtige Regulatoren des Knochenstoffwechsels, die Auswirkungen auf die 
Aktivität von Osteoblasten und Osteoklasten haben. 
Neben E3S kann auch Dehydroepiandrosteronsulfat (DHEAS) über OATPs in  
Knochenzellen aufgenommen und in aktives 17β-Östradiol umgewandelt werden. 
Darüber hinaus ist das OATP-Substrat Prostaglandin E2 (PGE2) ein potenter 
Induktor von Osteolyse und nach Aufnahme in die Zelle kann es schnell durch 
Oxidation inaktiviert werden. Mehrere OATPs können auch Methotrexat, ein Antifolat-
Medikament das Verwendung in der Behandlung von Osteosarkomen findet, 
transportieren. Indem OATPs  wichtige Regulatoren des Kochenstoffwechsels zur 
Verfügung stellen und möglicherweise die Wirksamkeit einer bestimmten 
Chemotherapie durch die Aufnahme von Krebsmedikamenten beeinflussen, könnten 
OATPs von Bedeutung für das Wachstum von Knochentumoren sein.  
Die Leber ist das wichtigste Entgiftungsorgan indem sie schädliche endogene 
Metaboliten und Xenobiotika aus dem Blutkreislauf entfernt und OATPs sind dafür 
bekannt, eine wichtige Rolle in diesem Prozess zu spielen. Derzeit ist das 
hepatozelluläre Karzinom (HCC) die dritthäufigste Ursache der weltweit durch Krebs 
verursachten Todesfälle. In der vorliegenden Arbeit wurden die Unterschiede in der 
OATP Expression in HCC, cholangiozellulärem Karzinom (CCC) und Metastasen von 
Primärtumoren in der Leber mit Proben von nicht-malignem angrenzenden Gewebe 
in 22 Patienten verglichen. Die stärkste Reduzierung der "leberspezifischen" 
OATP1B1 und OATP1B3 mRNA-Expression konnte im CCC mit Hilfe von TaqMan® 
real-time RT-PCR festgestellt werden und dieses Ergebnis könnte zumindest 
teilweise den Ersatz von Hepatozyten durch maligne Zellen aus Cholangiozyten und 
deren Vorstufen widerspiegeln. Ansonsten wurde deutlich, daß die mRNA-
Expression von OATP2A1 und OATP5A1 in primären und sekundären 
Lebertumoren, was auch auf  Protein-Ebene durch Immunfluoreszenzfärbung 
bestätigt werden konnte, hochreguliert ist. Darüber hinaus konnte sowohl auf mRNA- 
sowie auf Protein-Ebene gezeigt werden, daß die Hochregulation von OATP4A1 auf 
die Gruppe der Lebermetastasen beschränkt blieb.  
Die speziellen Expressionsmuster der verschiedenen OATP Transporter 
unterstreichen ihre möglichen spezifischen Funktionen in Tumorzellen, die den 
3. Introduction 
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Transport von wichtigen Signaltransduktionsmolekülen sowie von in der 
Tumortherapie verwendeten Medikamenten beinhalten kann. 
Zusammenfassend ist festzustellen, daß die vorliegenden Ergebnisse der häufigen 
Expression verschiedener OATP-Transporter in Brust-, Knochen-, Leber- und 
Eierstockkrebs die Grundlage für weitere Untersuchungen liefern bezüglich 
Transportprozesse für endogene und exogene Verbindungen in malignen und nicht-
malignen Erkrankungen. Dies könnte auch für weitere Untersuchungen hinsichtlich 
der Wirksamkeit einer bestimmten Behandlung in der Krebstherapie von Bedeutung 
sein.  
 
 
 
3. Introduction 
 
3.1. Membrane Transport 
 
3.1.1 The Plasma Membrane 
One important prerequisite of life is the appearance of barriers that are capable of 
separating order from randomness (i.e., the cell’s interior from the outside 
environment). Therefore, compartmentalization is necessary in order to assure the 
undisturbed course of life-maintaining functions under defined chemical and 
physiological conditions. 
This function is accomplished in all living cells by the plasma membrane, which forms 
a permeability barrier between the inside of the cell and the outside environment. In 
the case of eukaryotic cells, cell organelles like the nucleus and mitochondria are 
additionally surrounded by intracellular membranes. Moreover, all biomembranes are 
composed of noncovalently associated building blocks called phospholipids. The 
structures at the two ends of these molecules are very different. One end consists of 
a hydrophobic tail containing fatty acid chains while the other end has a hydrophilic 
head that includes polar groups such as phosphate. Both groups are linked by an 
organic molecule such as glycerol. Because of the differences in polarity throughout 
the molecule, phospholipids are considered to be amphipathic molecules. Their 
specific physical properties allow the formation of the typical sheet-like membrane 
structure. Under suitable conditions, phospholipids spontaneously form a bilayer 
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structure with the polar head facing outward, thereby shielding the hydrophobic fatty 
acid groups from water. The three main constituents of a mammalian cell membrane 
are phosphoglycerides, sphingolipids and cholesterol. Cholesterol in particular is 
highly abundant in the membranes of mammalian cells but is, for instance, absent 
from all plant cells. Cholesterol intercalates between phospholipids and serves an 
important structural role in membranes. 
A cellular membrane consisting of pure phospholipids would be impermeable to 
virtually all ions, amino acids, sugars and other important water-soluble molecules, 
and while it is tempting to think of the cellular membrane as a solid, impermeable 
wall, nothing could be farther from the truth. Indeed, the plasma membrane has the 
seemingly contradictory roles of confining and protecting the intracellular space and 
of also allowing the efficient and specific passage of structurally highly diverse endo- 
and xenobiotics across the membrane in both directions. Furthermore, the transfer of 
intercellular communication signals has to be assured. For this purpose, different 
classes of transport and receptor proteins are embedded in the phospholipid bilayer 
and are arranged in an amphipathic manner with the polar groups protruding out from 
the phospholipid bilayer into the aqueous space and the nonpolar groups largely 
buried in the hydrophobic interior of the membrane. This fluid mosaic model for the 
structure of membranes was first suggested by Singer & Nicolson [SINGER & 
NICOLSON, 1972].  
 
3.1.2. Mechanisms of Membrane Transport 
As mentioned above, the pure phospholipid bilayer represents an effective barrier, as 
only a small fraction of substances, such as the gases O2 and CO2, small 
hydrophobic molecules, and small uncharged polar molecules like ethanol may cross 
the membrane by simple diffusion.  
Other molecules are dependent on integral membrane proteins embedded in the 
plasma membrane and other cellular membranes for movement across the 
phospholipid bilayer. In order to achieve this movement, they either travel “downhill” 
along a concentration gradient from higher to lower concentrations, which does not 
involve consumption of energy, or they are moved “uphill” against a concentration 
gradient, which represents a thermodynamically unfavorable process that requires an 
external source of energy. An appropriate energy source is provided by the opposing 
concentration gradients of Na+ and K+ ions generated by an ATP-powered pump, the 
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so called Na+/K+ ATPase, in the plasma membrane. This pump uses the energy-
releasing hydrolysis of ATP to ADP + Pi to pump Na+ out of the cell and K+ into the 
cell. In addition to the chemical concentration gradient, an electrical gradient or 
potential is generated by the movement of ions. For example, positively charged K+ 
ions are released from the cell via K+ channels. The energy that is provided by ion 
concentration gradients and the electric potential are known as the electrochemical 
gradient, and can be used for “uphill” transport by different transport proteins to 
mediate the uptake of a broad range of molecules. 
 
3.1.3. Classes of Transport Proteins 
Most molecules would be incapable of crossing membranes without the assistance of 
specialized transport proteins and even the passage of substances usually able to 
diffuse through the cell membrane is frequently accelerated by specific proteins 
because their natural rate of diffusion is not fast enough to meet cellular needs. A 
common feature of all membrane transport proteins is the presence of multiple 
membrane-spanning elements that are thought to form a protein duct through the 
phospholipid bilayer, thereby avoiding contact of the hydrophilic substrates with the 
hydrophobic interior of the cell membrane (LODISH et al., 2008). 
Generally, membrane transport proteins can be divided into three classes: 
 
1. ATP-powered pumps 
2. Ion channels 
3. Transporters 
 
3.1.4. ATP-powered Pumps 
These transport proteins are characterized by the hydrolysis of ATP to ADP + Pi that 
releases the energy required to move ions or small molecules “uphill” against a 
concentration gradient. This process is considered to be “active transport” or “primary 
active transport” because these proteins work against a concentration gradient and 
are additionally providing the energy necessary for this process. An example would 
be the above-mentioned Na+/K+ ATPase. The class of ATP-powered pumps can be 
further divided into the four subclasses: P-class pumps, V-class proton pumps, F-
class proton pumps, and the ABC (ATP-binding cassette) superfamily. The ABC 
superfamily represents the most interesting subclass among the ATP-powered 
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pumps with regard to the transport of drugs across cell membranes. Forty-eight ABC 
transporters with diverse functions are known in humans [DEAN et al., 2001]. The 
first eukaryotic ABC protein was discovered because it conferred resistance to 
several drugs in different cell lines [KARTNER, RIORDAN & LING, 1983]. This 
multidrug-resistance (MDR) protein P-glycoprotein is the product of the ABCB1 gene 
and is frequently amplified in MDR cells, where it extrudes a large variety of drugs 
from the cell interior. Additionally, it was shown that the two copper-transporting P-
class pumps, ATP7A and ATP7B, transport platinum compounds out of the cell, 
thereby mediating drug resistance [KATANO et al., 2003; SAMIMI et al., 2004; 
KOMATSU et al., 2000]. 
 
3.1.5. Ion Channels 
Ion channels enable the passage of ions (Na+, K+, Ca2+, and Cl-), water, and small 
hydrophilic molecules through the phospholipid bilayer down their concentration 
gradients via facilitated transport or facilitated diffusion by forming a hydrophilic 
passageway through the phospholipid bilayer. The previously mentioned membrane 
K+ channel is a good example. Movement of ions through channels can occur at very 
high rates and channels are highly selective for the type of ion they transport.  
 
3.1.6. Transporters 
Transporters (solute carriers) have the ability to move a broad range of structurally 
unrelated compounds across cellular membranes. This class, the SLC (Solute 
carrier) superfamily, is, along with ABC transporters, involved in drug uptake. While 
ABC transporters are considered to be primary active transporters, SLC transporters 
are responsible for secondary active transport because they are dependent on 
established concentration and/or electrical gradients like that of the Na+ ion as an 
energy source for the “uphill” movement of their respective substrates.  
 
3.2. OATP – Organic Anion Transporting Polypeptides 
 
3.2.1. General Description of OATPs/Oatps 
Organic anion transporting polypeptides (OATPs in humans, Oatps in other species) 
belong to the SLC superfamily of transporters where they are members of the SLCO 
(solute carrier organic anion transporting polypeptides) gene family (Fig. 1). The first 
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Oatp was cloned in 1994 from rat liver [JACQUEMIN et al., 1994] and it has became 
evident that transport mediated by this Oatp was independent from Na+ as a 
cotransport [KULLAK-UBLICK et al., 1995; KÖNIG et al., 2000a]. Since then, 
OATPs/Oatps became a widely studied group of transporters and exhibit a broad 
range of substrate specifity. OATPs/Oatps catalyze the multispecific and sodium-
independent transport of various amphipathic organic anions, neutral compounds 
and also few cations including endogenous, amphipathic organic compounds like bile 
salts, thyroid hormones, prostaglandins, and steroid conjugates. In recent years, 
OATPs/Oatps raised attention as they revealed to play a critical role in the 
bioavailability of drugs, as they mediate the excretion of endogenous and exogenous 
compounds including drugs in clinical use [HAGENBUCH & GUI, 2008].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.2. Structure of OATPs/Oatps 
The first high resolution structure of an integral transmembrane protein by X-ray 
crystallography was published in 1985 [DEISENHOFER et al., 1985] and it has 
become clear that the determination of high-resolution structures is a bottleneck in 
Fig. 1 Phylogenetic tree of the OATP-gene superfamily. OATPs/Oatps with more than 
40% amino acid sequence identity are classified in the same family (OATP1, OATP2, 
OATP3, OATP4, OATP5, and OATP6). Members with more than 60% are classified in the 
same sub-family (e.g. OATP1A, OATP1B, and OATP1C). Human OATPs are given in all 
capitals, all other species are indicated with a small letter preceding the protein symbol 
Oatp. b, Bovine; c, chicken; m, mouse; r, rat; s, skate. [HAGENBUCH & GUI, 2008] 
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the characterization of membrane protein function because of difficulties in the 
purification, expression and crystallization of integral membrane proteins. Whereas 
membrane proteins make up about 20-30% of all open reading frames (ORFs) in fully 
sequenced genomes, only approximately 70 high-resolution membrane protein 
structures exist as compared to the thousands of solved structures of water-soluble 
proteins [NAM, JEON & KIM, 2009].  
OATPs/Oatps are transmembrane proteins made up of 643-722 amino acids 
[HAGENBUCH & MEIER, 2004] and no 3-D structure of an OATP/Oatp based on X-
ray crystallography has been generated thus far. Topological models including 3-D 
structures [MEIER-ABT et al., 2005] are based on computational methods and 
predict these proteins to have 9-12 transmembrane domains based on the general 
assumption that OATPs/Oatps contain 12 transmembrane-spanning regions (Fig. 2). 
This assumption is supported by experimental evidence regarding Oatp1a1 [WANG 
et al., 2008]. The 12-transmembrane structure results in the formation of six 
extracellular and five intracellular loops with both the N-terminal and C-terminal ends 
of the polypeptide chain located within the cell’s interior. It should be noted that 
extracellular loops 2 and 5 contain putative N-glycosylation sites that are conserved 
in most OATP/Oatp family members [HAGENBUCH & MEIER, 2004]. Post-
translational modification by N-glycosylation is important for OATPs/Oatps because it 
seems that this modification is responsible for both its functional activity and its 
delivery to the cell membrane [LEE et al., 2003]. According to the study of Lee et al., 
four asparagine residues at positions 62, 124, 135, and 492 are used in Oatp1a1 for 
N-glycosylation. This finding is in conflict with the study of Wang and coworkers, who 
suggested that only residues 124, 135, and 492 are used for glycosylation and that 
residue 62 is inaccessible for glycosylation due to its location within a 
transmembrane domain [WANG et al., 2008]. This discrepancy may be at least 
partially explained by differences in the experimental model systems like non 
mammalian X. laevis oocytes and mammalian cell lines. Moreover, Oatp1a1 
expressed in transfected yeast cells was entirely unglycosylated [LEE et al., 2003]. 
Differences were even reported within mammalian cell lines, as glycosylated and 
unglycosylated OATP1B1 were detected in transfected MDCK cells while only the 
glycosylated form was detected in HEK293 cells [KÖNIG et al., 2000b]. 
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3.2.3. Plasma Membrane Sorting of OATPs/Oatps 
PDZ (PSD-95/Discs-large/ZO-1) domains in proteins are generally composed of 80-
90 amino acids. They have been shown to influence drug transport by recruiting and 
stabilizing drug transporter proteins in the outer cellular membrane and by 
modulating their function via direct interaction with amino acids located at the C-
terminus of drug transporters [KATO, WATANABE & TSUJI, 2006]. It should be 
noted that PDZ motifs are generally conserved between humans and mice with the 
exception of PEPT1 and the OATP/Oatp family members [KATO, WATANABE & 
TSUJI, 2006]. Specific interactions with PDZ proteins were identified for several 
xenobiotic transporters, including OATP1A2, OATP3A1, and OATP1C1, using the 
yeast two-hybrid system [KATO et al., 2004]. Furthermore, it has been demonstrated 
with PDZK1 knock-out mice that an interaction with PDZK1 is required for the 
expression of rat Oatp1a1 on the intravenous surface of hepatocytes [WANG et al., 
2005]. While Oatp1a1 was expressed at high levels in rat hepatocytes, the protein 
remains largely in the intracellular space. This result was also confirmed in vivo when 
PDZK1 knock-out mice showed reduced clearance of bromosulfophthalein (BSP) 
after administration. Several OATPs lack putative PDZ motifs, including OATP2A1, 
Fig. 2 Predicted topological model of human OATP1B1 with twelve transmembrane domains. Amino acids 
conserved in 77 out of 97 mammalian OATPs/Oatps are indicated in black. Conserved cysteine residues 
are given in grey. Three N-glycosylation sites are indicated (Y) in extracellular loops E2 and E5. 
[HAGENBUCH & GUI, 2008] 
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which is predominantly localized intracellularly [BAO et al., 2002], and the two liver 
specific OATPs, OATP1B1 and OATP1B3, which are expressed on the basolateral 
membrane of human hepatocytes. 
 
3.2.4. Transport Mechanisms of OATPs/Oatps 
Since the discovery of the first Oatp in 1994 [JACQUEMIN et al., 1994], the 
underlying driving forces of OATP/Oatp-mediated transport have remained 
controversial. It is generally agreed that OATPs/Oatps act independently of ATP and 
Na+, Cl-, or K+ gradients, a finding confirmed by several studies [JACQUEMIN et al., 
1994; KULLAK-UBLICK et al., 1995; NOE et al., 1997; NOZAWA et al., 2004; 
MAHAGITA et al., 2007]. The first in vitro evidence for the assumption that 
OATPs/Oatps function as anion exchangers provided rat Oatp1a1, where extrusion 
of HCO3- was observed coupled to the influx of taurocholate in stably transfected 
HeLa cells but investigations if HCO3- can also serve as an counterion in vivo have 
not been performed [SATLIN et al., 1997]. Moreover, as intracellular pH is lower than 
extracellular pH, HCO3- gradients are unlikely to energize the transport of organic 
anions. Indeed, HCO3--driven transport has only been observed when the pH 
gradient was reversed and occurs opposite to the normal physiological condition. In 
another study, reduced glutathione (GSH) was reported as an Oatp1a1 counterion in 
cRNA injected X. laevis oocytes. This anionic tripeptide is present in virtually all cells 
at high concentrations (~10 mM) relative to its concentration in plasma (~10 µM) and 
this strong chemical gradient could provide a significant driving force for Oatp1a1-
mediated transport [LI et al., 1998]. Cotransport of GSH was also reported for the 
uptake of bile acids in X. laevis expressing OATP1B3 [BRIZ et al., 2006]. However, 
this result was not confirmed in another study [MAHAGITA et al., 2007]. These data 
support the hypothesis that OATP1B1 and OATP1B3 function as bidirectional 
facilitated diffusion transporters that are energized by the electrochemical substrate 
gradient rather than by exchangers or cotransporters that are directly coupled to the 
simultaneous movement of another substrate across the membrane [MAHAGITA et 
al., 2007]. The contribution of bicarbonate ion and GSH gradients to the OATP/Oatp 
driving force was also not supported by data from another study [NOZAWA et al., 
2004]. 
A common transport mechanism has been proposed for all OATPs/Oatps, in which 
substrates are translocated through a central, positively charged pore in a rocker-
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switch-type mechanism [MEIER-ABT et al., 2005]. However, it is unclear whether this 
transport mode involves the coupled movement of another solute across the 
membrane or occurs by facilitated diffusion through the putative central pore. 
OATP/Oatp transport activity may also be influenced by pH gradients, using the 
proton gradient across the membrane as the driving force. This process has been 
demonstrated for the transport of BSP by rat liver Oatp in transiently transfected 
HeLa cells [KANAI et al., 1996]. Furthermore, the uptake of pravastatin by OATP2B1 
was significantly increased in an acidic extracellular pH compared to neutral pH in 
transiently transfected HEK293 cells [KOBAYASHI et al., 2003]. In accordance with 
the previous study, significantly increased transport of estrone-3-sulfate (E3S) by 
OATP2B1 was seen at pH 5.0 compared to pH 7.4. As expected, transport of E3S 
was reduced by the proton ionophore FCCP only at acidic pH [NOZAWA et al., 
2004]. Interestingly, the opposite phenomenon was observed, where acidification of 
the intracellular compartment of HepG2 cells resulted in the increased uptake of 
glycocholic acid. These findings do not support a role for the pH-driven transport of 
glycocholic acid in these cells [MARIN et al., 2003]. A recent study showed that the 
transport activity of OATPs/Oatps is generally stimulated by an acidic extracellular 
environment and, additionally, that OATP/Oatp substrate transport leads to the 
stimulation of bicarbonate efflux, further supporting the theory that OATPs/Oatps act 
as anion exchangers [LEUTHOLD et al., 2009].  
These seemingly contrary data demonstrate that the ultimate driving force(s) for 
OATP-mediated transport as well as the manner in which its mechanism relates to 
the physiological role of OATPs is not yet clearly established. 
 
3.3. OATPs in Humans 
11 members of the OATP family have been identified in humans. They are classified 
in the six different superfamilies OATP1, OATP2, OATP3, OATP4, OATP5, and 
OATP6 [HAGENBUCH & MEIER 2004]. Human OATPs are expressed in a variety of 
tissues including intestine, liver, kidney, and brain, and are known to play a critical 
role in drug absorption, distribution, and the excretion of endogenous and exogenous 
compounds including drugs in clinical use [HAGENBUCH & GUI 2008]. While several 
OATP members like OATP3A1, OATP4A1, OATP2B1, and OATP2A1 could be 
identified in different tissues, some members exhibit unique cellular expression in 
distinct organs [HAGENBUCH & MEIER 2004; KÖNIG 2006]. Whereas OATP4C1 is 
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considered to be kidney-specific [MIKKAICHI et al., 2004], are OATP1B1 [ABE et al., 
1999; KÖNIG et al., 2000b] and OATP1B3 [KÖNIG et al., 2000a] exclusively 
expressed in human liver and involved in the hepatic clearance of a multitude of 
structurally unrelated compounds from the portal blood. Furthermore, five additional 
OATPs could be identified in this organ to date, either on protein or mRNA level, 
namely OATP1A2 [KULLAK-UBLICK et al., 1995], OATP2A1 [LU et al., 1996], 
OATP2B1 [TAMAI et al.. 2000], OATP3A1 [TAMAI et al., 2000] and OATP4A1 
[TAMAI et al., 2000]. Nevertheless, the tissue distribution and function of two OATP 
members, namely OATP5A1 and OATP6A1, is still less clear and needs to be further 
characterized. Only two studies about OATP6A1 on mRNA level are available 
suggesting a testis specific expression of human OATP6A1 [LEE et al., 2004; 
SUZUKI et al., 2003]. 
 
3.3.1. The OATP Superfamily of Uptake Transporters  
A new nomenclature was introduced in the year of 2004 for the systematic 
classification of OATP/Oatp protein and gene names [HAGENBUCH & MEIER, 
2004]. Therefore, old protein names for the human OATPs are given in parentheses 
as they are still appearing in literature, especially when published before 2004. 
 
OATP1A2 (OATP, OATP-A) was isolated in 1995 from a human liver cDNA library 
[KULLAK-UBLICK et al., 1995]. In liver, OATP1A2 expression could be localized to 
the cholangiocytes but not to hepatocytes [LEE et al., 2005]. Other tissues with 
confirmed OATP1A2 expression include small intestine [GLAESER et al., 2007], the 
brush border membrane in the distal nephron [LEE et al., 2005], and the blood brain 
barrier [GAO et al., 2000]. OATP1A2 consists of 670 amino acids and can be found 
in liver in its glycosylated form with a molecular mass of 85 kDa [KULLAK-UBLICK et 
al., 1997a]. In contrast, the mass of OATP1A2 in brain comprises only approximately 
60 kDa, due to incomplete glycosylation [GAO et al., 2000]. Transport of endogenous 
substrates include the thyroid hormones triiodothyronine (T3) and thyroxin (T4) 
[FUJIWARA et al., 2001], the steroids E3S [LEE et al., 2005] and DHEAS [KULLAK-
UBLICK et al., 1998], the bile acids cholate and taurocholate [KULLAK-UBLICK et 
al., 1995], and bilirubin [BRIZ et al., 2003]. Among OATP1A2 transported xenobiotics 
are BSP [KULLAK-UBLICK et al., 1995], but also several drugs like the antibiotics 
ciprofloxacin and levofloxacin [MAEDA et al., 2007], the statins pitavastatin [FUJINO 
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et al., 2005] and rosuvastatin [HO et al., 2006], and the anticancer agents 
methotrexate [BADAGNANI et al., 2006] and imatinib [HU et al., 2008]. 
 
OATP1B1 (LST-1, OATP2, OATP-C) was independently cloned by three different 
groups in 1999 from human liver cDNA libraries [ABE et al., 1999; HSIANG et al., 
1999; KÖNIG et al., 2000b]. OATP1B1 is considered to be liver specific and protein 
expression is restricted to the basolateral membrane of hepatocytes  where it is 
supposed to play an important role in the clearance of organic anions from the blood 
[KÖNIG et al., 2000b]. OATP1B1 consists of 693 amino acids with an approximate 
molecular mass of 58 kDa when unglycosylated and 84 kDa after glycosylation 
[KÖNIG et al., 2000b]. Furthermore, OATP1B1 has been extensively studied in the 
past and represents the best characterized OATP regarding substrate specificities. 
OATP1B1 transports a broad range of endogenous and exogenous substances 
which is in part overlapping with the substrate spectrum of OATP1B3. Endogenous 
substrates of OATP1B1 are hormones and their conjugates like E3S [CUI et al., 
2001], estradiol-17β-glucuronide [ABE et al., 1999], DHEAS [ABE et al., 1999], T3 
and T4 [ABE et al., 1999], bile acids like cholate [CUI et al., 2001], glycocholate 
[KULLAK-UBLICK et al., 2001] and glycoursodeoxycholate [MAEDA et al., 2006], 
bilirubin [BRIZ et al., 2003], and the eicosanoid prostaglandin E2 (PGE2) [ABE et al., 
1999]. Many xenobiotics are transported by OATP1B1 including BSP [CUI et al., 
2001], the antibiotics benzylpenicillin [TAMAI et al., 2000] and rifampicin [VAVRICKA 
et al., 2002], and the statins fluvastatin [KOPPLOW et al., 2005], pitavastatin 
[HIRANO et al., 2004] and pravastatin [HSIANG et al., 1999].  
Due to the broad substrate specifity, high expression levels of OATP1B1 at the 
basolateral membrane of hepatocytes and its involvement into uptake of endogenous 
substances and xenobiotics it can significantly contribute to interindividual differences 
in drug effects. Several polymorphisms in the SLCO1B1 gene have been described 
affecting either protein function or localization in vitro [TIRONA et al., 2001]. 
Moreover, impacts of SLCO1B1 polymorphisms in vivo have been reported. In a 
study including 41 healthy volunteers, individuals with a 512TC genotype had on 
average a 106 % higher pravastatin plasma concentration compared to the 521TT 
genotype group [NIEMI et al., 2004]. In addition, similar to the in vivo finding with 
pravastatin, the AUC (area under curve) for repaglinide in subjects with the 521CC 
genotype was 107 % and 188 % higher, respectively, compared to individuals with 
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521TC and 521CC genotype in a study with 56 healthy volunteers [NIEMI et al., 
2005].  
 
The second member of the human OATP1 sub-family is OATP1B3 (LST-2, OATP-8). 
OATP1B3 was independently cloned by two different groups from liver cDNA libraries 
[ABE et al., 2001; KÖNIG et al., 2000a]. Similar to OATP1B1, OATP1B3 expression 
is liver specific but in contrast to OATP1B1 which is expressed throughout the liver 
lobe, OATP1B3 expression is found to be condensed around the central vein [ABE et 
al., 2001]. OATP1B3 is a glycoprotein of 702 amino acids and a molecular weight of 
approximately 120 kDa in human liver which is reduced to approximately 65 kDa 
when unglycosylated. It shares 80 % amino acid identity with OATP1B1. OATP1B3 
belongs to the group of well characterized OATPs and many substrates for 
OATP1B3 have been defined using mammalian cell lines or the X. laevis expression 
system. OATP1B3 transports a broad range of different substrates which is partly 
overlapping with the one of OATP1B1. Endogenous substrates of OATP1B3 are T3 
and T4 [KULLAK-UBLICK et al., 2001], E3S [KULLAK-UBLICK et al., 2001], 
estradiol-17β-glucuronide [CUI et al., 2001], cholate and taurocholate [BRIZ et al., 
2006], and bilirubin [BRIZ et al., 2003].  Various xenobiotics are transported by 
OATP1B3, like BSP [KULLAK-UBLICK et al., 2001], the cytotoxic drugs methotrexate 
[ABE et al., 2001], docetaxel and paclitaxel [SMITH et al., 2005] and mycophenolic 
acid (MPA) -7-O-glucuronide (MPAG) [PICARD et al., 2010], a conjugate of MPA, 
which is the active moiety of the immunosuppressive drug mycophenolate mofetil 
(MMF). It could be furthermore demonstrated in the work of Picard et al. that the 
pharmacokinetics of MPA are significantly influenced by the common T334G 
polymorphism in the SLCO1B3 gene in renal transplant patients receiving MMF in a 
cyclosporine-free immunosuppressive regimen. 
 
OATP1C1 (OATP-F) was cloned from a human brain cDNA library [PIZZAGALLI et 
al., 2002]. Highest expression levels were found in brain, where it seems to be 
expressed at the blood-brain barrier [PIZZAGALLI et al., 2002] and furthermore in 
Leydig cells in the testis [PIZZAGALLI et al., 2002]. OATP1C1 consists of 712 amino 
acids with a calculated mass of approximately 78 kDa [PIZZAGALLI et al., 2002]. 
OATP1C1 is thought to have a narrower substrate specificity compared to the other 
members of the OATP1 sub-family but it could be shown that OATP1C1 transports 
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thyroid hormones (reverse T3 and T4)  with high affinity [PIZZAGALLI et al., 2002]. 
However, it also transports the common OATP substrates E3S, estradiol-17β-
glucuronide and BSP [PIZZAGALLI et al., 2002]. In an interesting recent study it 
could be demonstrated that OATP1C1 transport activity is insensitive to extracellular 
acidic pH due to the lack of a conserved His in the third TMD at the position 130 
[LEUTHOLD et al., 2009]. 
 
OATP2A1 (PGT) was originally cloned from a human kidney cDNA library [LU et al., 
1996]. In contrast to the members of the OATP1 sub-family, OATP2A1 is considered 
to be widely expressed in the human body [LU et al., 1996]. OATP2A1 is a protein of 
643 amino acids with a calculated molecular mass of approximately 70 kDa. 
Interestingly, OATP2A1 has a quite unique spectrum of substrates as it transports 
prostaglandins and other eicosanoids but not the typical OATP substrates like BSP, 
E3S, and estradiol-17β-glucuronide. 
 
OATP2B1 (OATP-B) was cloned from a human kidney cDNA library [TAMAI et al., 
2000]. OATP2B1 expression could be determined in a variety of different tissues 
including liver [KULLAK-UBLICK et al., 2001], placenta [ST.-PIERRE et al., 2002], 
and heart [GRUBE et al., 2006]. Moreover, OATP2B1 might represent the OATP 
family member with the best defined distribution of protein expression at the cellular 
level. OATP2B1 expression was determined at the sinusoidal membrane of 
hepatocytes [KULLAK-UBLICK et al., 2001], at the basal membrane of the 
syncytiotrophoblasts [ST.-PIERRE et al., 2002], furthermore in the endothelial cells of 
capillaries, small arteries and veins of the heart [GRUBE et al., 2006], at the luminal 
membrane of brain endothelial cells [BRONGER et al., 2005], at the basolateral 
membrane of the non-pigmented epithelium in the ciliary body [GAO et al., 2005], at 
the brush border membrane of the small intestine [KOBAYASHI et al., 2003], and at 
the apical membrane of Caco2 cells [SAI et al., 2006]. OATP2B1 is a glycoprotein 
consisting of 709 amino acids with different molecular masses depending on the 
organ in which it is expressed. Whereas the molecular mass in liver is approximately 
85 kDa [KULLAK-UBLICK et al., 2001], and approximately 95 kDa in ciliary body 
[GAO et al., 2005], two different bands at 85 and 95 kDa were observed in brain 
[BRONGER et al., 2005] possibly due to different states of glycosylation. Concerning 
substrate specificity, OATP2B1 was firstly characterized having a rather narrow 
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range of substrates because with assays performed at pH 7.4 only the “classic” 
OATP substrates BSP [KULLAK-UBLICK et al., 2001], E3S and DHEAS 
[PIZZAGALLI et al., 2003] could be identified. However, if performed at acidic pH, a 
broader substrate range for OATP2B1 could be observed including taurocholate, 
fexofenadine, pravastatin [NOZAWA et al., 2004], and glibenclamide [SATOH et al., 
2005].  
 
OATP3A1 (OATP-D) is the single member of the human OATP3 sub-family. 
Interestingly, two different splice variants, OATP3A1_v1 and OATP3A1_v2 could be 
identified which are expressed in a tissue dependent pattern. OATP3A1_v1 was 
originally cloned from a human kidney cDNA library [TAMAI et al., 2000] and 
OATP3A1_v2 was cloned from a human brain cDNA library [HUBER et al., 2007]. 
OATP3A1 is ubiquitously expressed on mRNA level with highest levels found in 
testis, brain, heart, and spleen [ADACHI et al., 2003; HUBER et al., 2007]. At the 
protein level, the two splice variants could be detected in different tissues [HUBER et 
al., 2007]. OATP3A1_v1 consists of 710 amino acids and OATP3A1_v2 of 692 with 
calculated molecular weights of approximately 76 and 74 kDa, respectively. The two 
proteins only differ at their C-terminal end. It should be noted that OATP3A1 shares 
about 97 % amino acid identity with the rat and mouse ortholog making it the most 
conserved member within the OATP family [HAGENBUCH & MEIER, 2004]. Both 
splice variants reveal a similar range of transported substrates when expressed in X. 
laevis oocytes and CHO cells, including prostaglandin E1 (PGE1), PGE2, and T4 
[HUBER et al., 2007]. 
 
OATP4A1 (OATP-E) was originally cloned from a human kidney cDNA library [TAMAI 
et al., 2000] and a human hippocampus cDNA library [FUJIWARA et al., 2001]. 
Expression of OATP4A1 is widely and could be confirmed at the mRNA level by 
northern blot or RT-PCR analysis in a variety of different tissues including placenta, 
lung, liver, heart, skeletal muscle, kidney, and pancreas [TAMAI et al., 2000; 
FUJIWARA et al., 2001]. Moreover, it could be detected at the protein level on the 
apical membrane of syncytiotrophoblasts in the placenta [SATO et al., 2003].  The 
OATP4A1 protein contains 722 amino acids with a molecular mass of approximately 
65 kDa in brain and placenta [SATO et al., 2003]. The substrate range of OATP4A1 
is relatively narrow, with E3S, estradiol-17β-glucuronide, taurocholate, 
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benzylpenicillin, T3, and T4 amongst its substrates [TAMAI et al., 2000; FUJIWARA 
et al., 2001]. 
 
OATP4C1 (OATP-H) was isolated from a human kidney cDNA library [MIKKAICHI et 
al., 2004]. Based on northern blot analysis, OATP4C1 was demonstrated to be 
kidney specific and the rat ortholog Oatp4c1, sharing 80 % amino acid identity, could 
be localized on the basolateral membrane of the proximal tubule cells by 
immunohistochemistry [MIKKAICHI et al., 2004]. The human OATP4C1 is composed 
of 724 amino acids with a calculated mass of 79 kDa. Like OATP4A1, OATP4C1 
exhibits a narrow spectrum of transported compounds including cyclic AMP (cAMP), 
methotrexate, T3, and T4 [MIKKAICHI et al., 2004]. 
 
OATP5A1 (OATP-J) mRNA expression has been identified using real-time RT-PCR 
in various organs including thymus, heart, skeletal muscle, prostate, and fetal brain 
[OKABE et al., 2008] but the protein expression and function has not been thoroughly 
characterized so far. An expression profile of OATP5A1 protein can be viewed at 
http://www.proteinatlas.org/tissue_profile.php?antibody_id=25062 with strongest 
expression in cortical cells from the adrenal gland and follicle cells of the ovary. The 
putative OATP5A1 protein contains 848 amino acids with a calculated molecular 
mass of 92 kDa. 
 
OATP6A1 (OATP-I, GST, OATPY) was cloned from a human testis cDNA library 
[SUZUKI et al., 2003]. It has been shown by RT-PCR that OATP6A1 mRNA is 
predominantly expressed in testis but weak expression could also be detected in 
spleen, brain, fetal brain, and placenta [SUZUKI et al., 2003; LEE et al., 2004]. 
OATP6A1 is a predicted protein of 719 amino acids with a calculated molecular mass 
of approximately 79 kDa. Like OATP5A1, the protein expression and function of 
OATP6A1 needs further characterization. 
 
3.4. The Relevance of OATPs in Cancer 
Although further investigations are needed to define the physiological role of the 
OATP family of transporters in healthy tissues, it is already well established that 
numerous OATPs are aberrantly expressed under pathophysiological conditions.  
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Hepatocellular Carcinoma (HCC): 
The first studies of OATPs in malignant disease focused on the expression of 
OATP1A2 in the HepG2 hepatoblastoma cell line and its ability to act as a specific 
bile acid uptake system [KULLAK-UBLICK et al., 1996] that could be used to deliver 
bile acid-coupled anticancer drugs like chlorambucil-taurocholate into cancer cells 
[KULLAK-UBLICK et al., 1997b]. In HCC, it was demonstrated by western blot 
analysis that the liver-specific OATPs, OATP1B1 and OATP1B3, are downregulated 
relative to the surrounding normal liver tissue and that the expression of the two liver-
specific OATPs are absent in the HepG2 cell line. The study was accomplished using 
a self-generated antibody that recognized both OATP family members and which 
could be useful as part of an optimized marker panel suitable for the identification of 
HCCs in diagnostically problematic cases [CUI et al., 2003]. Findings of reduced 
OATP1B1 expression in HCC reported by Zollner and coworkers [ZOLLNER et al., 
2005] taken together with the finding that OATP1B3 shows decreased expression in 
HCC tissue [CUI et al., 2003] indicate that the strategy of targeting liver cancer cells 
via bile acid-coupled chemotherapeutic drugs needs further careful evaluation.  
 
Gastrointestinal Cancers: 
In contrast to HCC, overexpression of the liver specific OATP1B3 was demonstrated 
in gastrointestinal cancers of the stomach, colon, and pancreas by 
immunohistochemistry [ABE et al., 2001]. Interestingly, OATP1B3 expression by 
primary colon cancer was also maintained in a metastatic lesion of the lymph node. 
Moreover, it was shown that the anticancer agent methotrexate is transported by 
OATP1B3 and that the expression of OATP1B3 in gastrointestinal cancer cell lines 
like KatoIII and PK-8 is accompanied by increased sensitivity to this drug [ABE et al., 
2001]. 
 
Colorectal Cancer (CRC): 
The OATP1B3 mRNA and protein are significantly overexpressed in colorectal 
cancer but no difference in expression was observed for the closely related OATP1 
family members OATP1A2 and OATP1B1 between tumor and normal colon tissue 
[LEE et al., 2008]. Remarkably, the staining pattern of OATP1B3 in the colorectal 
tumor tissue showed a primarily cytoplasmic pattern that is very different from the 
membrane staining in liver, which served as control tissue. Unexpectedly, OATP1B3-
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expressing colon cancer cells (RKO, HCT-8) exhibited a survival advantage relative 
to empty vector-transfected control cells when both are treated with the 
chemotherapeutic drug camptothecin. It seems that OATP1B3 overexpression 
interferes with the transcriptional activity of p53 and its downstream targets [LEE et 
al., 2008]. Moreover, the antiapoptotic effect of OATP1B3 seems to be dependent on 
its transporter function because overexpression of an OATP1B3 variant with a loss-
of-function point mutation did not affect p53 activity [LEE et al., 2008]. Additionally, 
increased expression of OATP4A1 could be observed in CRC by micro-array 
analysis [ANCONA et al., 2006]. Compatible with this result is a study of OATP 
expression in inflammatory bowel disease (IBD), where a highly significant 
overexpression of OATP2B1 and OATP4A1 mRNA was detected in specimens 
collected from inflamed ulcerative colitis (UC) patients compared to specimens from 
non-inflamed UC [WOJTAL et al., 2009]. Patients with long-standing IBD have a 
higher risk in developing CRC [XIE & ITZKOWITZ, 2008]. In another study, the role 
of the prostaglandin uptake transporter OATP2A1 was investigated in CRC [HOLLA 
et al., 2008]. It was demonstrated that OATP2A1 is downregulated in CRC relative to 
normal mucosa and that the PGE2-extruding pump MRP4 is upregulated in CRC 
[REID et al., 2003]. PGE2 in particular has been identified as an important mediator 
of cancer progression in CRC [SHENG et al., 2001]. Prostaglandins can act via G-
coupled membrane receptors or via nuclear peroxisome proliferator-activated 
receptors (PPARs) [GUPTA et al., 2000]. The import of PGE2 into cancer cells is of 
importance as it facilitates the removal of PGE2 from the extracellular milieu, which is 
followed by inactivation via intracellular 15-hydroxyprostaglandin dehydrogenase (15-
PGDH) [NOMURA et al., 2004].  
 
Breast Cancer: 
The role of OATP uptake transporters is of special interest in hormone-responsive 
cancers because many OATPs are known to conduct hormones and their conjugates 
across cell membranes. In normal breast tissue, OATP2B1 is expressed at high 
levels in cells from the myoepithelium. However, in tumor-bearing tissue, OATP2B1 
was most apparent in areas of invasive ductal carcinoma and lost its association with 
myoepithelial cells [PIZZAGALLI et al., 2003]. As OATP2B1 was identified as steroid-
sulfate carrier [PIZZAGALLI et al., 2003], it could be an important factor that 
contributes, together with elevated levels of 17β-hydroxysteroid dehydrogenase I and 
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aromatase enzymes, to high intratumoral levels of active 17β-estradiol (E2) [ARIGA 
et al., 2000; MIYOSHI et al., 2001]. Furthermore, it has been demonstrated that the 
liver-specific OATP1B3 is expressed in breast cancer tissue and has been identified 
as a potent prognostic marker in a study of 102 specimens of invasive ductal breast 
carcinoma using immunohistochemistry [MUTO et al., 2007]. A recent study 
conducted in our laboratory revealed that the expression of OATP3A1, OATP4A1 
and, OATP2B1 is significantly altered at the mRNA level between malignant and 
adjacent non-malignant breast cancer specimens [WLCEK et al., 2008]. All of these 
transporters were identified as having E3S as a substrate, which is highly abundant 
in plasma and can be converted within the tumor cells to active estrogen. 
 
Bone Cancer:  
In another study examining OATP expression patterns in bone tumors and benign 
bone cysts we were able to show the expression of all OATPs except OATP1B1, 
OATP1B3 and OATP6A1 in bone tumors. OATP3A1 and OATP4A1 were most 
widely found. Furthermore, mRNA levels of OATPs were generally reduced in 
malignant specimens derived from osteosarcomas and bone metastases compared 
to benign bone lesions from 21 patients [LIEDAUER et al., 2009]. Distinct differences 
were also observed between the MG-63 and HOS bone cancer cell lines and primary 
bone cells (i.e., human osteoblast outgrowth cells and bone marrow stromal cells). 
OATPs may have diverse effects on bone and bone disease progression as many of 
them are known to transport sex steroid hormones, which are important regulators of 
bone turnover that influence the activity of osteoblasts and osteoclasts [SVOBODA, 
HAMILTON & THALHAMMER, 2010]. As a result, OATPs may also play an important 
role in malignant bone disease. Moreover, the OATP substrate PGE2 was identified 
as a potent promoter of bone resorption [HIKIJI et al., 2008]. Several OATPs are also 
involved in the transport of methotrexate, an antifolate drug used in the treatment of 
osteosarcoma (see section 2.4.1). Thus, OATPs may be of importance in the 
regulation of bone tumor growth and progression by providing important regulators of 
bone homeostasis and by influencing the efficacy of chemotherapy regimens through 
the uptake of certain anticancer drugs.  
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Brain Tumors: 
Altered expression patterns of OATPs were also studied in brain tumors (gliomas). 
The expression of OATP1A2 and OATP2B1 was confirmed in the blood-brain barrier 
but was not found in glioma cells, suggesting that the uptake of drugs proceeds 
through the endothelial cells but that entry into glioma cells may be impaired 
[BRONGER et al., 2005]. Moreover, expression of the testis-specific OATP6A1 was 
also identified in medulloblastomas, and its localization to the membrane and its 
limited expression in normal tissues suggest that OATP6A1 could be a target for 
antibody-based immunotherapy [OBA-SHINJO et al., 2008]. 
 
Lung Cancer: 
Serological analysis of recombinant expression libraries (SEREX) has led to the 
identification of OATP6A1 as a cancer/testis (CT) antigen expressed in lung cancer 
[LEE et al., 2004]. Therefore, OATP6A1 could represent a potential target for 
monoclonal antibody-based cancer therapy, as it should be associated with cell 
surface expression, which is not the case for most other CT antigens [LEE et al., 
2004]. 
 
Prostate Cancer: 
In a recent study, SLCO1B3 was found to be markedly overexpressed in prostate 
cancer compared to normal prostate or benign prostate hyperplasia tissue and a 
statistically significant association of a specific SLCO1B3 haplotype with survival of 
patients with prostatic cancer was identified. Furthermore, it could be shown that 
OATP1B3 is mediating testosterone uptake into cells and enhanced testosterone 
uptake may therefore shorten the time to androgen independence in prostate cancer 
[HAMADA et al., 2008]. 
 
3.4.1. OATPs as Transporters for Chemotherapeutic Agents 
It is well known that the overexpression of ATP-powered efflux pumps, such as P-
glycoprotein (P-gp) coded by the ABCB1 gene, induces drug resistance for cytotoxic 
agents including paclitaxel [BAEKELANDT et al., 2000]. However, drug uptake 
mechanisms into tumor cells might also be important determinants for therapy 
efficacy because they ensure a sufficient intracellular concentration of 
chemotherapeutic agents. In addition to the mode whereby drugs enter cells mostly 
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via passive diffusion at a rate related to their lipophilicity, there is increasing evidence 
that xenobiotics, and therefore also cytotoxic agents, utilize a mechanism of 
“hitchhiking” with carriers that act on natural, often unknown, endogenous substrates 
[DOBSON & KELL, 2008]. This idea suggests that uptake transporters might also 
have a profound impact on the success of a particular chemotherapeutic treatment. 
In one of the first investigations of this concept, it was shown that the cytostatic agent 
chlorambucil is transported by OATP1A2 when coupled to a bile acid. This strategy 
was designed to specifically target hepatocellular carcinoma cells [KULLAK-UBLICK 
et al., 1997b]. Furthermore, the transport of Bamet-R2 and Bamet-UD2 by OATP1A2 
and OATP1B1 was demonstrated using cRNA injected X. laevis oocytes [BRIZ et al., 
2002]. Bamet-R2 and Bamet-UD2 are compounds that consist of the anticancer 
agent cisplatin coupled to bile acid side chains. It should be noted that uncoupled 
cisplatin does not seem to be transported by OATPs [BRIZ et al., 2002]. The 
antifolate drug methotrexate was identified as a substrate for the liver specific 
OATPs, OATP1B1 and OATP1B3, which may help to explain methotrexate-induced 
liver dysfunction [ABE et al., 2001], OATP1A2 [BADAGNANI et al., 2006], and the 
kidney specific OATP4C1 [MIKKAICHI et al., 2004] also showed methotrexate uptake 
activity. The liver specific OATP1B3 was also found to be a high affinity transporter of 
the microtubule stabilizing agents paclitaxel and docetaxel in studies using cRNA-
injected X. laevis oocytes [SMITH et al., 2005]. This finding is indirectly supported by 
the work of Gui et al., who could show inhibition of OATP1B3 mediated uptake of 
estradiol-17β-glucuronide into stably transfected CHO cells by paclitaxel and, 
interestingly, this inhibition effect was also observed when using OATP1B1 
transfected cells [GUI et al., 2008]. OATP1B3-mediated paclitaxel transport could not 
be confirmed in a different study using stably transfected HEK293 cells 
[YAMAGUCHI et al., 2008].  
In conclusion, inter-individual differences in OATP expression may help explain the 
varied responses of cancer patients treated with OATP substrates and suggests the 
need for systematic investigations of all OATP family members in regard to tumor 
expression and their ability to transport chemotherapeutic agents, which could help to 
avoid giving toxic therapies to patients unlikely to benefit from them. 
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4. Aims of the Thesis 
 
The “gold standard” treatment for solid tumors is the removal of the tumor load by 
surgery. However, surgical removal alone is often not sufficient to prevent tumor 
recurrence and metastasis. Therefore, chemotherapeutic treatment and/or radiation 
therapy are additionally applied. However, the efficacy of those approaches is 
reaching its limits, particularly in cases of advanced tumors. 
The efficacy of chemotherapy is highly dependent on the intracellular concentration 
of the chemotherapeutic agent, which is determined by the rate of the drug’s entry 
into the target cells, by the rate of biotransformation via drug metabolizing enzymes, 
and by the extrusion of the drug or its metabolites via specific drug efflux pumps.  
 
The aim of this thesis was to evaluate the role of a family of plasma membrane 
transporters, the organic anion transporting polypeptides (OATPs), in the delivery of 
endogenous and xenobiotic compounds into solid tumors from the ovary, mammary 
glands, liver, and bone. Some members of the OATP family have already been 
shown to be capable of transporting anticancer agents as well as steroid hormones 
and their conjugates, which could be important determinants for tumor progression in 
hormone dependent cancers like cancers of the breast or ovary. However, despite 
the great progress made concerning the role of OATPs in physiology since their 
discovery in 1994, only piecemeal information is available concerning the expression 
of the 11 human OATP family members in cancers of the breast, bone, liver and 
ovary. Therefore, their expression should be assessed in malignant tissue samples 
and compared to adjacent normal tissue and benign tumors in order to identify 
aberrant patterns of OATP expression. Moreover, the whole OATP family should be 
characterized with regard to its capability to transport the anticancer agent paclitaxel, 
which is frequently used to treat ovarian and metastatic breast cancer. This will be 
accomplished by studying the uptake of radiolabeled paclitaxel into OATP-cRNA 
microinjected X. laevis oocytes. In a final study, the impact of OATP expression will 
be investigated in a large cohort of ovarian cancer patients and correlated with the 
patients’ survival. 
As a result of the development of drug resistance and toxic side effects, the success 
of different chemotherapeutic approaches is still not ideal. The studies planned in this 
thesis will contribute to a more personalized therapy by determining if the presence 
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or absence of certain drug uptake transporters has an impact on the success of 
these therapies. This contribution will allow patients to avoid therapies unlikely to 
benefit them and will prevent toxic effects caused by drug-drug interactions. 
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Abstract  
 
Paclitaxel is an anti-tumour agent used for the treatment of ovarian cancer with 
pronounced tumour accumulation. The diverse pharmacokinetics and variable 
efficacy of this substance are attributable to the fact that several ATP-binding 
cassette transporters are involved in the cellular efflux of the compound. To 
investigate whether organic anion transporter polypeptides (OATPs) may also act as 
cellular carriers for paclitaxel, we studied the mRNA expression of all known human 
OATPs in the two ovarian carcinoma cell lines OVCAR-3 and SK-OV-3. TaqMan® 
real-time RT-PCR analysis revealed expression of several OATPs in both cell lines 
with the highest mRNA levels for OATP1B1 and 1B3 in the SK-OV-3 cells, which was 
correlated with higher intracellular paclitaxel concentration in this cell line. Further 
studies using cRNA microinjected Xenopus laevis oocytes revealed OATP1B1 and 
OATP1B3 as high affinity transporters of paclitaxel with apparent Km values of 0.6 µM 
and 1.6 µM, respectively. Therefore, OATB1B1 and OATP1B3 may play a key role in 
the uptake of paclitaxel into ovarian cancer cells during therapy. 
 
Keywords: Ovarian cancer, paclitaxel, OATPs, PCR, SK-OV-3, OVCAR-3  
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1. Introduction 
Ovarian cancer is often diagnosed at an advanced stage because early symptoms 
are inconspicuous and reliable diagnostic biomarkers are not available [1]. This 
contributes to a poor 5-year overall survival rate (< 40%) and a high death rate [2]. 
After initial surgery on the tumour, a combination of paclitaxel together with platinum 
derivatives is applied in standard chemotherapy [3]. Although high response rates to 
this initial regimen are observed, a relapse is seen in two-thirds of patients due to the 
rapid development of drug resistance [4, 5], which is often caused by a reduced 
accumulation of the drug in cancer cells.  
It is well-established that overexpression of ATP-powered efflux pumps such as P-
glycoprotein (P-gp) or MDR1 coded by the ABCB1 gene induces drug resistance for 
cytotoxic agents, including paclitaxel [6]. Indeed, taxane resistance due to 
overexpression of P-glycoprotein (MDR1) has been shown in ovarian cancer [7]. 
Furthermore, overexpression of the multidrug-resistance-related proteins MRP2 
(ABCC2), MRP3 (ABCC3) and MRP7 (ABCC10) have been identified as paclitaxel-
resistance factors in various cell lines and tumour tissues, including HER-2-amplified 
breast carcinoma and non-small-cell lung cancer [8, 9, 10]. However, uptake 
mechanisms into tumour cells might be even more important for the efficacy of 
anticancer drugs because they are important determinants for intracellular drug 
concentration [11].  
One of the most important cellular drug uptake mechanisms in humans is via 
members of the organic anion transporting polypeptide family (OATP) [12, 13]. 
Official nomenclature differentiates between genes and protein using the term 
“SLCO” and “OATP”, respectively [14]. To facilitate readability and understanding of 
the manuscript, “OATP” is used for both genes and proteins. OATPs are expressed 
in a variety of tissues [15] and tumours [16, 17] mediating the transport of 
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endogenous and exogenous compounds and clinically used drugs [12, 13, 18]. 
Studies have shown that uptake transporters can confer sensitivity to anticancer 
agents [19, 20, 21, 22, 23, 24] as shown for the OATP1B3 substrate methotrexate 
[19]. This may be important for therapy because expression of OATP greatly varies in 
tumour cell lines [25].  
 Cellular uptake of paclitaxel is known to be facilitated by OATP1B3 at least in 
Xenopus laevis oocytes [26] and by the organic anion transporter 2 (OAT2; gene 
symbol: SLC22A7) [27] expressed predominantly in human liver and kidney [28]. 
However, whether OAT2 is also expressed in human cancer cells is unknown. As 
OATPs exhibit overlapping substrate specificity, we hypothesised that additional 
OATPs may also contribute to the uptake of paclitaxel. To gain further insight into the 
possible role of OATP transporters in ovarian cancer, we characterised the mRNA 
expression profiles of all 11 known transporters and studied the uptake of paclitaxel 
in the estrogen responsive OVCAR-3 [29] and the estrogen-independent SK-OV-3 
[30] ovarian cancer cell lines. Moreover, we investigated the specific paclitaxel 
transport activity of all 11 known OATPs by injecting X. laevis oocytes with their 
corresponding cRNA. Our results demonstrated that paclitaxel uptake in OVCAR-3 
and SK-OV-3 cells correlates with OATP1B1 and OATP1B3 mRNA expression, 
indicating an important role of these transporters in tumour therapy.  
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2. Material and Methods 
 
2.1. Materials 
[3H]paclitaxel (740 GBq/mmol) was purchased from American Radiolabelled 
Chemicals (St. Louis, MO). The ovarian carcinoma cell lines OVCAR-3 and SK-OV-3 
were obtained from the ATCC (Manassas, VA). Foetal Calf Serum (FCS) was 
obtained from Invitrogen (Carlsbad, CA). The ovarian carcinoma cell lines were 
maintained in phenol-red-free RPMI-1640 medium supplemented with L-glutamine 
(PAN-Biotech GmbH, Aidenbach, Germany), 10% FCS and 1% penicillin (10.000 
U/ml)/streptomycin (10 mg/ml) solution (Invitrogen) in a humidified atmosphere at 37 
°C with 5% CO2.  
 
2.2. TaqMan® real-time RT-PCR 
Total RNA from OVCAR-3 and SK-OV-3 cancer cells was isolated using the 
RNeasy® Mini kit (Qiagen, Hilden, Germany), and the RNA was treated with RNase 
free DNase (Qiagen) to remove possible genomic DNA. The concentration, purity 
and integrity of RNA samples were determined on a Nanodrop ND-1000 (Kisker-
Biotech, Steinfurt, Germany) and agarose gel electrophoresis. A total of 1 µg of total 
RNA was reverse transcribed in 20 µl reactions using the High Capacity cDNA RT kit 
(Applied Biosystems, Foster City, CA) with the provided random hexamer primers 
and RNase inhibitor (Applied Biosystems) according to the manufacturer’s 
instructions. TaqMan® Gene Expression Assays (Applied Biosystems) were 
purchased for all 11 human OATPs and four transporters from the ABC family (Table 
1). Control assays for the ACTB (PN 4326315E) and HPRT (PN 4310890E) genes 
were also purchased from Applied Biosystems. Prefabricated primers and probes for 
the endogenous control genes GAPDH and RPL13A were obtained from 
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PrimerDesign (PrimerDesign Ltd., Southampton, UK). TaqMan® real-time RT-PCR 
was performed in an amplification mixture volume of 10 µl containing 5 µl 2x 
TaqMan® Gene Expression PCR Master Mix                                                                                                                                                                                                                   
(Applied Biosystems), 0.5 µl of the appropriate Gene Expression Assay, 10 ng 
template cDNA diluted in 4 µl nuclease free water, and 0.5 µl nuclease free water. 
Thermal cycling conditions were 2 min at 50 °C and 10 min at 95 °C, followed by 40 
cycles of 15 s at 95 °C and 1 min at 60 °C on the 7900HT Sequence Detection 
System (Applied Biosystems) equipped with a 96-well fast cycling block. Results 
were imported into DataAssist™ 2.0 software (Applied Biosystems) for automated 
data analysis using the comparative Ct (∆∆Ct) method [31]. Thus, a normalisation 
factor (NF) was calculated by averaging the Ct values of the four endogenous control 
genes ACTB, GAPDH, HPRT, and RPL13A via the geometric mean. Relative 
quantities (RQ) for every sample were then calculated by the formula RQ = 2 (–∆Ct) / 2(–
∆Ctreference)
, where ∆Ct = Average Ct – NF. The standard deviation (SD) was calculated 
for Ct values of the technical replicates and was used to calculate the RQMin and 
RQMax:  
RQMin = 2(–∆Ct – SD) / 2(–∆Ctreference)  
RQMax = 2(–∆Ct + SD) / 2(–∆Ctreference)  
according to the DataAssist™ v2.0 Software User Instructions (Applied Biosystems). 
 
2.3. Transport experiments in cell lines  
Cells that were 80-90% confluent were washed three times and incubated for 15 min 
(37 °C) in 12-well plates with 1 ml Krebs-Henseleit buffer (KHB, 118 mM NaCl, 23.8 
mM NaHCO3, 4.8 mM KCl, 1.0 mM KH2PO4, 1.2 mM MgSO4, 12.5 mM HEPES, 5.0 
mM glucose, and 1.5 mM CaCl2, pH 7.4) [32]. Subsequently, cells were treated with 1 
ml/well KHB containing 18.5 nM [3H]paclitaxel. Unlabelled paclitaxel was added to a 
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final concentration of 5 µM. Uptake was measured after 1, 2, 4, 6 and 10 min or, 
alternatively, at graded concentrations (0.5, 1.0, 2.5, 5.0 and 10.0 µM paclitaxel) after 
1 min of incubation, which had been determined to be within the linear range of 
uptake. Control studies were performed at 4 °C to determine temperature-insensitive 
paclitaxel accumulation. Paclitaxel transport was stopped by adding ice-cold KHB, 
followed by three washes. The amount of paclitaxel in the cells was determined by 
first adding 300 µl 0.2 N NaOH to each well. After 12 h at 4 °C, 150 µl 0.4 N HCl and 
4 ml Emulsifier-Safe™ scintillation cocktail (PerkinElmer) were added, and 
[3H]paclitaxel was measured in an LS6500 scintillation counter (Beckman Coulter, 
Fullerton, CA). Protein determination was performed using a BCA™ Protein Assay 
(Pierce, Rockford, IL) with bovine serum albumin as the standard. 
 
2.4. Cytotoxicity assay 
A total of 1000 cells/well were seeded on 96-well plates. After 48 h, cells were 
treated with graded concentrations of paclitaxel (0.5, 1.0, 2.0, 4.0, 6.0, 10.0 and 50.0 
nM) or 0.1% solvent dimethyl-sulfoxide alone. Viability was measured after 48 h 
using the CellTiter-Glo® Assay (Promega, Madison, WI) and a Victor™ microplate 
reader (PerkinElmer, Waltham, MA). Corresponding IC50 values were calculated by 
non-linear regression analysis using GraphPad Prism 5 software (GraphPad, La 
Jolla, CA). 
 
2.5. Preparation of OATP cDNA for the expression in X. laevis oocytes 
The plasmids containing the human full-length cDNA from OATP1B1 (pSPORT1) 
and OATP1B3 (pSPORT1) were originally cloned from a human liver cDNA library, 
and OATP2B1 (pCMV6-XL4) was cloned from a human brain cDNA library [33]. 
OATP1A2 (pDRIVE, IHS1382-8428120), OATP2A1 (pOTB7, EHS1001-6793541), 
5. Results: Paclitaxel Transport by OATPs 
 56 
and OATP4C1 (pENTR223.1, OHS4559-99620240) full-length cDNA clones were 
purchased from Open Biosystems (Thermo Fisher Scientific, Huntsville, AL). The 
lacking stop codon in the OATP4C1 clone was reconstructed by PCR using 0.5 mM 
dNTPs, 12.5 pmol of each primer, 0.5 U Hot Start Phusion® DNA polymerase 
(Finnzymes, Espoo, FI) and 1x HF buffer (Finnzymes) in a final volume of 25 µl. The 
following primer sequences were used (start codon in bold): forward: 5’-CC ACC 
ATG AAG AGC GC-3’ and reverse: 5’-TCA CCC TTC TTT TAC TAT TTT GTT G-3’. 
Thermal cycling conditions were 98 °C for 30 s, followed by 25 cycles of 98 °C for 10 
s, 62 °C for 20 s, and 72 °C for 1 min on a MyCycler™ (Bio-Rad, Hercules, CA). The 
obtained full-length OATP4C1 PCR fragment was subcloned into the pJET1.2 vector 
(Fermentas, St.Leon-Rot, Germany) using blunt-end cloning and the CloneJET PCR 
cloning kit (Fermentas) according to the manufacturer’s instructions. OATP1C1 
(pBluescriptR, IRAKp961I0832Q) and OATP4A1 (pOTB7, IRALp962P0734Q) 
plasmids were purchased from Imagenes (Berlin, Germany). To obtain full-length 
cDNA sequences of OATP3A1 and OATP5A1 we purchased total RNA from normal 
human ovary (MVP™, Stratagene, La Jolla, CA). Total testis RNA (Clontech 
Laboratories, Inc., Mountain View, CA) for the cloning of OATP6A1 was donated  by 
Dr. D. Mechtcheriakova (Department of Pathophysiology, Medical University of 
Vienna, Austria). Reverse transcription was performed by preincubation of 0.4 µg 
total RNA with 0.5 µg oligo(dT) primers in a volume of 11 µl for 5 min at 65 °C. 
Subsequently, 9 µl of reverse transcription master mix was added, containing 0.5 mM 
of dNTPs (Fermentas), 20 U of RNaseOUT™ (Invitrogen, Carlsbad, CA), 200 U of 
RevertAid™ H Minus M-MuLV reverse transcriptase (Fermentas) and 1x reaction 
buffer in a final volume of 20 µl and incubation at 45 °C for 1 h, followed by 70 °C for 
10 min. The sequence of OATP6A1 was amplified from 50 ng of testis cDNA and the 
sequence of OATP3A1 and OATP5A1 from 50 ng of ovary cDNA using 0.5 mM of 
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dNTPs, 12.5 pmol of each primer, 0.75 µl DMSO, 0.5 U Hot Start Phusion® DNA 
polymerase (Finnzymes, Espoo, FI) and 1x GC buffer (Finnzymes) in a final volume 
of 25 µl. Primer sequences were the following (start codons are in bold): OATP3A1, 
forward: 5’-A AGG ATG CAG GGG AAG AAG C-3’, reverse: 5’-GCC CTC CTT TAG 
TCA CTA TAA AAC GG-3’; OATP5A1, forward: 5’-TGA ATT CTA AGC GCC ATG 
GAC GAA-3’, reverse: 5’-TCT TCC ATT TTC AAG CTT CAG GAG G-3’; and 
OATP6A1, forward: 5’-A GCC ATG TTC GTA GGC GTC GC-3’, reverse: 5’- ATC 
ACA ATG ATG ATC CAG TTA CAA GTC AG-3’. PCR conditions for OATP3A1 were 
98 °C for 30 s, followed by 40 cycles of 98 °C for 10 s, 68.5 °C for 20 s and 72 °C for 
1 min on a Bio-Rad MyCycler™. The conditions for OATP5A1 and OATP6A1 were 
identical except for annealing at 66 °C. The purified cDNA was then cloned into the 
pJET1.2 vector using the CloneJET PCR cloning kit (Fermentas). Sequences of 
OATP3A1, 5A1 and 6A1 were checked by forward and reverse full-length 
sequencing (MWG, Ebersberg, Germany), and compared to the appropriate 
reference sequences (OATP3A1 transcript variant 1: NM_013272.3; OATP5A1: 
NM_030958.1; OATP6A1: NM_173488.3). In OATP3A1, we found a polymorphism 
for 1083G>C, resulting in the amino acid exchange of Glu294Asp. For OATP5A1, we 
determined an SNP at 1406C>G affecting the amino acid exchange of Leu264Val. 
No polymorphisms were found in OATP6A1. 
 
2.6. Linearisation, template preparation, and in vitro transcription of OATP cRNA 
All plasmid inserts were verified for correct sequence and orientation by sequencing 
(MWG). For the in vitro synthesis of cRNA, the cDNA clone of OATP4A1 was 
linearised with BglII, and Mlul was used for the linearisation of OATP1B1 and 
OATP1B3 plasmids. For OATP3A1, OATP4C1, OATP5A1, and OATP6A1 we used 
XbaI for linearisation. OATP1C1 was linearised with Acc65I and OATP2A1 with DraI. 
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All restriction enzymes were obtained from Fermentas. After linearisation, proteinase 
K and 0.5% SDS treatment, plasmid DNA was purified by phenol/chloroform 
extraction and ethanol precipitation. OATP1A2 and OATP2B1 sequences were 
amplified from plasmid using 0.5 mM of dNTPs, 12.5 pmol of each primer, 0.75 µl 
DMSO, 0.5 U Hot Start Phusion® DNA polymerase (Finnzymes) and 1x GC buffer 
(Finnzymes) in a final volume of 25 µl. Standard vector primers (M13) were used for 
amplification: forward: 5’- TGT AAA ACG ACG GCC AGT-3’ and reverse: 5’- CAG 
GAA ACA GCT ATG ACC-3’. Thermal cycling conditions were as follows: 98 °C for 
30 s, 25 cycles of 98 °C for 15 s, 55 °C for 20 s, and 72 °C for 1 min on a Bio-Rad 
MyCycler™. The obtained OATP1A2 and OATP2B1 PCR products were gel-purified 
and used as templates for in vitro transcription. 5’ capped cRNAs were transcribed in 
vitro using 1 µg of template DNA and either T7 or SP6 mMESSAGE mMACHINE® kit 
(Ambion, Austin, TX) according to the manufacturer’s instructions. Subsequently, the 
cRNAs were polyA-tailed using the polyA tailing kit (Ambion) according to the 
protocol. The polyA cRNA was then purified using the MEGAClear™ kit (Ambion). 
The concentration, purity, and integrity of cRNA samples were determined on a 
Nanodrop ND-1000 (Kisker-Biotech) and by denaturing gel electrophoresis. 
 
2.7. Paclitaxel transport studies in Xenopus laevis oocytes 
Preparation of stage V-VI oocytes from X. laevis was performed as previously 
described [34]. Briefly, X. laevis frogs (NASCO, USA) were anaesthetised by exposing 
them for 15 min to a 0.2% solution of MS-222 (methane sulfonate salt of 3-
aminobenzoic acid ethyl ester; Sandoz Company) before surgical removal of parts of 
the ovaries. Follicle membranes from isolated oocytes were enzymatically digested 
with 2 mg/ml collagenase (Type 1A, Sigma). One day after isolation, the oocytes 
were injected with 10-50 nl of water either alone, to determine non-specific uptake of 
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paclitaxel, or containing approximately 200 ng/µl cRNA of each OATP. Injected 
oocytes were incubated in ND96 buffer (90 mM NaCl, 1 mM KCl, 1 mM MgCl2, 1 mM 
CaCl2, and 5 mM HEPES, pH adjusted to 7.4, supplemented with 100 U/ml penicillin 
and 100 µg/ml streptomycin) at 18 °C for 48 hours before performing transport 
experiments with buffer exchange every day. Uptake studies were carried out in 
single oocytes using at least 12 oocytes per data point. Oocytes were washed three 
times with 3 ml substrate-free uptake buffer (100 mM NaCl, 2 mM KCl, 1 mM MgCl2, 
1 mM CaCl2, 10 mM HEPES, pH adjusted to 7.4 with TRIS) and incubated with 400 
µl uptake buffer containing 20 nM [³H]paclitaxel and 1% ethanol at room temperature 
for the appropriate time points. To avoid unspecific binding of [³H]paclitaxel to the 
surfaces of laboratory plastic wares, all solutions containing [³H]paclitaxel were 
manipulated using glass ware. For kinetic analysis, the uptake of radiolabelled 
paclitaxel was measured over a range of concentrations from 20 to 1180 nM using 60 
min incubations, which had been determined to be within the linear component of 
uptake. Uptake was corrected for non-specific influx using water-injected oocytes 
from the same batch in each experiment. Uptake was stopped by the addition of 3 ml 
ice-cold uptake buffer, and oocytes were washed three times with buffer before being 
placed in scintillation vials for dissolution with 10% SDS overnight. Radioactivity was 
measured in a liquid scintillation counter (LS-6500; Beckman, California, USA). 
 
2.8. Western blot analysis of OATP1B1 and 1B3 in X. laevis oocytes 
Oocyte protein expression and membrane localisation of human OATP1B1 and 1B3 
were confirmed by western blot using membrane and cytosolic protein fractions from 
OATP1B1- and 1B3-injected oocytes prepared according to Bianchi and Driscoll [35]. 
A total of 10 µg of protein was separated on 10% separating gels, blotted on PVDF 
membranes and probed using an antibody against OATP1B1/1B3 (#BM5541, Acris, 
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Herford, Germany), diluted 1:250 in TBS-T (20 mM Tris, 145 mM NaCl, 0.05% Tween 
20, pH 7.6) containing 5% milk powder [36]. On control blots, an antibody to α-tubulin 
(Sigma, T-5168) was diluted 1:8000 in TBS-T containing 5% milk powder. The HRP-
conjugated secondary antibody (#315-036-003, Jackson ImmunoResearch, Suffolk, 
UK) was used at a dilution of 1:10000 in TBS-T.  
 
2.9. Data analysis 
For kinetic analysis, data were fitted to the Michaelis-Menten (hyperbolic) model. 
Kinetic parameters were estimated using Prism 5 software (GraphPad) for Michaelis-
Menten kinetics: 
     V=Vmax·S/(Km+S)      
Where V is the rate of reaction, Vmax is the maximum velocity, Km is the Michaelis 
constant, and S is the substrate concentration. Unless otherwise indicated, values 
are expressed as means ± SD of at least 12 individual oocytes per data point. 
Statistical differences from control values were evaluated using a Students’ t-test, 
and the level of statistical significance was set at P < 0.05. 
 
3. Results 
3.1. mRNA expression of OATPs and OAT2 in ovarian cancer cells  
To assess the role of OATP transporters for paclitaxel uptake, we investigated the 
mRNA expression of all 11 human OATPs in the human ovarian carcinoma cell lines 
OVCAR-3 and SK-OV-3. Interestingly, expression of the liver-specific OATP1B3 was 
up to 204-fold higher in SK-OV-3 cells compared to OVCAR-3 cells (Table 2). Even 
more pronounced was the difference for OATP1B1 expression, as this transporter 
was only found in SK-OV-3 cells. Furthermore, a different expression pattern was 
also observed for OATP2B1, which was 71-fold higher in SK-OV-3 cells, and for 
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OATP5A1, which was 85-fold higher in the OVCAR-3 cell line. OATP mRNA of 1A2, 
2A1, 3A1, 4A1, 4C1, could be detected in OVCAR-3 and SK-OV-3, although the 
observed distribution was more balanced. Expression of OATP1C1, OATP6A1, and 
OAT2 mRNA was below the detection limit in both cell lines.  
 
 
3.2. Transport of paclitaxel in ovarian cancer cell lines 
Based on the different expression of OATPs in OVCAR-3 and SK-OV-3 cells, we also 
expected altered intracellular paclitaxel levels. In both cell lines, uptake of paclitaxel 
was linear with time, up to 90 sec, and with respect to 5 µM paclitaxel concentrations 
(data not shown). For kinetic analysis, an incubation time of 1 min was therefore 
chosen, showing a typical Michaelis-Menten kinetic for the uptake of paclitaxel into 
the OVCAR-3 cells with a Vmax of 517.5 ± 86.2 pmol/mg protein/min and a Km value 
of 17.2 ± 4.1 µM (Fig. 1A). However, transport of paclitaxel into the SK-OV-3 cell line 
was far more pronounced, showing an uptake rate of 1660 ± 126 pmol/mg 
protein/min at a concentration of 10 µM. Based on the limited solubility of this drug in 
serum-containing cell culture medium, saturation kinetics could not be observed (Fig. 
1B)  
 
3.3. Paclitaxel transport studies in X. laevis oocytes 
To investigate whether other OATPs besides OATP1B3 contribute to paclitaxel 
uptake into OVCAR-3 and SK-OV-3 cells, uptake studies were performed for all 11 
known human OATPs in X. laevis oocytes injected with cRNA coding for each of the 
OATP family members. Using radiolabelled paclitaxel (20 nM for 60 min), uptake in 
OATP1B1- and 1B3-expressing oocytes was significantly higher compared to the 
water control (5.3- and  3.9-fold, respectively; P < 0.0001), while no other OATP 
5. Results: Paclitaxel Transport by OATPs 
 62 
favoured paclitaxel uptake (Fig. 2). The time course of [³H]paclitaxel uptake by 
OATP1B1- and 1B3-expressing oocytes was linear with time for up to 60 min (Figs. 
3A and B). The kinetic constants for this uptake revealed saturable transport in 
OATP1B1-expressing oocytes, with a Vmax of 12.3 ± 0.4 fmol/oocyte/min and a Km 
value of 0.6 ± 0.04 µM. OATP1B3-injected oocytes showed a 2.4-fold higher Vmax for 
paclitaxel (30 ± 1.6 fmol/oocyte/min) and a 2.7-fold higher KM value of 1.6 ± 0.13 µM 
compared to OATP1B1 (Figs. 3C and D). OATP1B1 and 1B3 protein expression in X. 
laevis oocytes was also confirmed by western blot analysis (see Figs. 3E and F). 
 
3.4. Paclitaxel cytotoxicity 
Despite differences in uptake kinetics, both ovarian carcinoma cell lines showed a 
similar sensitivity to paclitaxel. After treatment of cells with various concentrations of 
paclitaxel for 48 h, an IC50 of 3.05 ± 1.18 and 4.63 ± 1.08 nM was observed for 
OVCAR-3 and SK-OV-3 cell lines, respectively (Figs. 4A and B). 
 
3.5. Expression of paclitaxel efflux transporters in ovarian cancer cell lines 
Given that differences in the expression of OATP1B3 and 1B1 between the two cell 
lines did not correlate with the observed similar paclitaxel cytotoxicity, we further 
investigated the expression of four major paclitaxel efflux transporters in these two 
cells lines. We observed up to 18-fold higher mRNA expression levels for MRP2 and 
MRP3 in SK-OV-3 cells (Table 3), indicating a higher efflux of paclitaxel out of the 
cytoplasm into the cellular supernatant. MDR1 and MRP7 were approximately similar 
in distribution between the two cell lines.  
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4. Discussion 
In the present study, we investigated OATPs and their correlation with paclitaxel 
uptake in the two ovarian cancer cell lines OVCAR-3 and SK-OV-3 and in cRNA-
microinjected Xenopus laevis oocytes.  
By investigation of all 11 known OATPs by TaqMan® real-time RT-PCR, we found 
that OATP1B1, 1B3 and 2B1 were far more significantly expressed in SK-OV-3 cells, 
whereas OATP1A2, 4C1 and 5A1 were primarily present in OVCAR-3 cells. The two 
transporters OATP1C1 and OATP6A1 were not detectable in either cell line. It should 
be noted that expression of OAT2, which was previously shown to mediate the 
uptake of paclitaxel in X. laevis oocytes, was below the detection limit in both cell 
lines. Our data are consistent with the previous work of Okabe and coworkers, who 
also showed similar differences of OATP expression in OVCAR-3 and SK-OV-3 cells 
[25]. However, contrary to their study, we were unable to confirm expression of 
OATP6A1 in the OVCAR-3 cell line.  
 Based on these differences in OATP expression, we further investigated the 
concentration-dependent uptake of paclitaxel in these two cell lines. Indeed, SK-OV-
3 cells showed about 3-fold higher uptake rates at 10 µM paclitaxel (1660 ± 126 
pmol/mg protein/min) compared to OVCAR-3 cells (518 ± 86 pmol/mg protein/min). 
Differences between the two cell lines were also seen in the uptake kinetics. 
Whereas paclitaxel uptake was linear in SK-OV-3 cells, uptake in OVCAR-3 cells 
followed classical Michaelis-Menten kinetics with a KM value of 17.25 ± 4.12 µM.  
 To date, only OATP1B3 has been confirmed as a high-affinity paclitaxel 
transporter [26] within the OATP family. Furthermore, uptake of paclitaxel was 
significantly reduced in the OATP1B3 expressing cell line HepG2 but not in 
OATP1B3-deficient PR-HepG2 cells by the OATP1B3 substrate and inhibitor 
bromosulfophtalein [37]. By systematically investigating the transport properties of 
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paclitaxel for all 11 OATPs using the X. laevis oocytes expression system, we were 
able to identify OATP1B1 as an additional uptake protein for paclitaxel. Indirect 
involvement of OATP1B1 in taxane transport has been reported earlier by Gui et al., 
who showed inhibition of the OATP1B1 substrate estradiol-17β-glucuronide by 
paclitaxel in stable transfected CHO cells [38]. An involvement of OATP1B1 in 
hepatic clearance of paclitaxel may explain the finding of a pharmacogenetic 
investigation of variants of the SLCO1B3 gene. In the study of Smith et al. [39], 
differences of paclitaxel pharmacokinetics did not associate with different OATP1B3 
variants, one of which has recently been shown to influence the pharmacokinetics of 
mycophenolate [40].  
 The far higher uptake rates of paclitaxel in SK-OV-3 cells prompted us to 
hypothesise that this could correlate with cytotoxicity. However, paclitaxel inhibited 
the growth of OVCAR-3 and SK-OV-3 cells with comparable IC50 values (3.1 nM and 
4.6 nM), indicating that increased paclitaxel uptake in SK-OV-3 cells might be 
counteracted by efflux mechanisms. Several ABC transporters have been shown to 
successfully extrude paclitaxel from the cells. Importantly, it has been demonstrated 
that MDR1 and MRP2 as well as MRP3 and MRP7 mediate paclitaxel transport [7, 8, 
9, 10]. By using TaqMan® real-time RT-PCR, we identified higher expression levels of 
MRP2 and MRP3 in SK-OV-3 cells, whereas differences of MDR1 and MRP7 mRNA 
expression were moderate. MRP2 and MRP3 may therefore facilitate increased 
efflux of paclitaxel in SK-OV-3 cells.  
 Our data suggest that, in addition to OATP1B3, OATP1B1 might be an even 
more important determinant of paclitaxel uptake in ovarian cancer cells based on its 
lower Km value in X. laevis oocytes (0.6 µm vs. 1.6 µM), which is in the range of the 
mean plasma concentration in patients (0.85 ± 0.21 µM) after 24 h of infusion [41]. 
OATP1B1- and 1B3-mediated paclitaxel transport is of clinical importance, as both 
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transporters share a wide, overlapping substrate spectrum that includes HMG-CoA 
reductase inhibitors such as fluvastatin and pitavastatin, the antibiotic rifampicin, and 
the endothelin receptor antagonist BQ123 [42]. The hepatic uptake rate of both 
transporters might be reduced by drug competition, thus resulting in increased blood 
levels. Therefore, inter-individual expression levels of OATP1B1 and 1B3 in the 
basolateral membrane of hepatocytes might be responsible for differences in the 
occurrence of toxic side effects such as neutropenia, neuropathy and cardiac effects 
during paclitaxel therapy. Such drug-drug interactions have been reported for the 
OATP1B1 and 1B3 substrates pravastatine and bosentan [43, 44] when 
concomitantly administered with clarithromycin and cyclosporine or rifampicin, 
respectively.  
 In conclusion, we found that OATP1B1 and 1B3 are high affinity and active 
paclitaxel transporters in transfected X. laevis oocytes, which may also be true for the 
uptake of this compound in human liver and ovarian cancer cells.   
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Table 1     
Overview of the applied gene expression assays (ABI) used for  real time RT-PCR 
analysis 
Protein 
name Assay IDa            Context sequence (5'→3') 
Accession                                 
number 
     
OATP1A2 hs00245360_m1 ACCACCTTCAGATACATCTACCTCG 
  
NM_134431.2 
NM_021094.2 
OATP1B1 hs00272374_m1 ATTCCACATCATTTTCAAGGGTCTA NM_006446.3 
OATP1B3 hs00251986_m1 CTAACTTTTTGTTGGGAATCATAAC NM_019844.2 
OATP1C1 hs00213714_m1 CTCCTACCAAGGAACCAAACCTGTC NM_017435.3 
OATP2A1 hs00194554_m1 GCGCTTGCTGGCCTGGCTGCCATCT NM_005630.1 
OATP2B1 hs00200670_m1 CTGCCAGGAAGGGCAAGGACTCTCC NM_007256.2 
OATP3A1 hs00203184_m1 CTCCTCGCTCTATATAGGAATCCTG NM_013272.2 
OATP4A1 hs00249583_m1 CAGAGACCTGCCTCTCTCCATCTGG NM_016354.3 
OATP4C1 hs00698884_m1 TGGGAGAAAGCACTGATGTCACTGA NM_180991.4 
OATP5A1 hs00229597_m1 TCATTGGAAACTGGTGGAGTGGATT NM_030958.1 
OATP6A1 hs00542846_m1 CTACACTTGCAGGACTTGTTTTAAT NM_173488.3 
OAT2 hs00198527_m1 AGCCTCTGGTGGGTGCCTGAGTCTG NM_153320.2 
NM_006672.3                      
MDR1 hs00184500_m1 AGACATGACCAGGTATGCCTATTAT NM_000927.3 
MRP2 hs00166123_m1 CACCTCCAACAGGTGGCTTGCAATT NM_000392.3 
MRP3 hs00358656_m1 CAGCTGCTCAGCATCCTGATCAGGT NM_001144070.1 
NM_003786.3 
MRP7 hs00375716_m1 CCCAGCTCAGATCCCAGTTGGCTAT NM_033450.2 
aApplied Biosystems    
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Table 2        
Expression levels of OATP mRNA in ovarian cancer cell linesa 
Protein 
name 
OVCAR-3   SK-OV-3 
        
 RQ RQ-RQMin RQMax-RQ  RQ RQ-RQMin RQMax-RQ 
        
OATP1A2 1.00 0.1 0.06  0.07 0.00 0.00 
OATP1B1 ND ND ND  1.00 0.01 0.01 
OATP1B3 1.00 0.00 0.00  203.93 6.87 7.11 
OATP1C1 ND ND ND  ND ND ND 
OATP2A1 1.00 0.08 0.09  0.45 0.04 0.05 
OATP2B1 1.00 0.00 0.00  70.57 0.99 1.01 
OATP3A1 1.00 0.05 0.05  0.18 0.00 0.00 
OATP4A1 1.00 0.03 0.03  6.29 0.05 0.05 
OATP4C1 1.00 0.02 0.03  0.07 0.00 0.00 
OATP5A1 1.00 0.00 0.00  0.01 0.00 0.00 
OATP6A1 ND ND ND  ND ND ND 
 
amRNA expression levels relative to OVCAR-3; Maximum values are in bold; ND, 
transcripts were below the detection limit 
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Table 3        
Expression levels of ABC transporter mRNA in ovarian cancer cell linesa 
Protein 
name 
OVCAR-3   SK-OV-3 
        
 RQ RQ-RQMin RQMax-RQ  RQ RQ-RQMin RQMax-RQ 
        
MDR1 1.00 0.00 0.00  1.73 0.02 0.02 
MRP2 1.00 0.01 0.01  18.31 1.15 1.23 
MRP3 1.00 0.04 0.05  5.30 0.28 0.29 
MRP7 1.00 0.01 0.02  0.93 0.00 0.00 
 
amRNA expression levels relative to OVCAR-3; Maximum values are in bold; ND, 
transcripts were below the detection limit 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Results: Paclitaxel Transport by OATPs 
 75 
 
Legends to the Figures  
 
Figure 1: Time- and concentration-dependent uptake of paclitaxel in the ovarian 
cancer cell lines OVCAR-3 and SK-OV-3. The time-dependent uptake of 5 µM 
paclitaxel was measured in OVCAR-3 (A) and SK-OV-3 (B) cells at 1, 2, 4, 6, and 10 
min. Concentration-dependent paclitaxel uptake for OVCAR-3 (C) and SK-OV-3 (D) 
cells was evaluated after an incubation time of 1 min at 37 °C with paclitaxel 
concentrations ranging from 0.5 to 10 µM. Uptake values were corrected (net values; 
dotted line) for temperature-insensitive paclitaxel accumulation measured at 4 °C 
after 1 min of incubation for each concentration (dashed line). Kinetic constants were 
calculated by non-linear least-square analysis. Data represent the mean ± SD of 
triplicate determinations. 
 
Figure 2: Paclitaxel uptake in X. laevis oocytes. The uptake of [³H]paclitaxel was 
measured in X. laevis oocytes injected with human OATP cRNA after 60-min 
incubation with 20 nM [³H]paclitaxel. Data are given as percent of controls ± SD of at 
least 12 oocytes per data point. OATPs showing significantly higher (***P < 0.001) 
uptake rates compared to water-injected oocytes (control) are marked with asterisks. 
 
Figure 3: Time course and concentration-dependent uptake of paclitaxel by 
OATP1B1- and OATP1B3-expressing X. laevis oocytes. The time-dependent uptake 
of 20 nM [³H]paclitaxel was measured for OATP1B1 (A) and OATP1B3 (B) cRNA-
injected oocytes. Water-injected X. laevis oocytes were included as a negative 
control. Concentration-dependent paclitaxel uptake for OATP1B1- (C) and 
OATP1B3- expressing oocytes (D) was evaluated after an incubation time of 60 min 
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with various paclitaxel concentrations ranging from 20 to 1180 nM. Data represent 
the mean ± SD of triplicate determinations. Protein expression of OATP1B1 (E) and 
1B3 (F) in X. laevis oocytes was confirmed by western blot analysis of cRNA injected 
(+) and water injected (-) oocytes. 
 
Figure 4: Cytotoxic effect of paclitaxel. An ATP-based detection assay was used to 
assess paclitaxel cytotoxicity in OVCAR-3 (A) and SK-OV-3 (B) cells. Eight 
measurements were performed for each dilution point (mean ± SD). 
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Fig. 1.  
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Fig. 2.  
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Fig. 3 
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Fig. 4.  
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(OATP) genes in human breast carcinoma 
Katrin Wlcek, Martin Svoboda, Theresia Thalhammer, Franz Sellner,                     
Georg Krupitza, and Walter Jäger. 
Cancer Biol Ther. 7 (2008) 1450-1455. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5. Results: OATPs in Breast Cancer 
 82 
 
 
5. Results: OATPs in Breast Cancer 
 83 
 
 
 
 
5. Results: OATPs in Breast Cancer 
 84 
 
 
 
 
5. Results: OATPs in Breast Cancer 
 85 
 
 
 
 
5. Results: OATPs in Breast Cancer 
 86 
 
 
 
 
5. Results: OATPs in Breast Cancer 
 87 
 
 
5. Results: OATPs in Breast Cancer 
 88 
 
 
 
 
5. Results: OATPs in Bone Cancer 
 89 
 
Different expression patterns of organic anion transporting 
polypeptides in osteosarcomas, bone metastases and aneurysmal 
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ABSTRACT 
Transmembrane transporters for endobiotics and drugs from the organic anion 
transporting polypeptide (OATP) family are expressed in the liver and may be altered 
in cancer. Thus, we investigated mRNA expression of all eleven OATPs in paired 
cancerous and adjacent non-cancerous specimens (n=22) from hepatocellular 
(HCC), cholangiocellular carcinomas (CCC) and liver metastases (MLT). TaqMan® 
real-time RT-PCR analysis revealed that all OATPs except OATP1C1 and 6A1 are 
expressed in the majority of tissues samples. With the exception of OATP1A2, they 
are also expressed in primary hepatocytes and HepG2 cells. In comparing cancerous 
and non-cancerous specimens, we found that mRNA expression levels were reduced 
for OATP1B1, 1B3, 1A2 and 2B1 and increased for OATP2A1, 3A1 and 5A1 in 
cancer samples. Differences were also seen between different tumor types. While 
downregulation of OATP1A2 and 1B3 mRNA expression was most pronounced in 
CCC, marked up-regulation of OATP4A1 and 5A1 mRNA was observed in MLT. 
Immunofluorescence studies for OATP2A1, 5A1 and 4A1 revealed immunoreactive 
plasma membrane staining in cancer cells. Staining of cytokeratin-19 positive cells in 
proliferating bile ducts was observed for OATP2A1 and 4A1. Further studies in 
HepG2 cells revealed reduced mRNA levels of all OATPs except OATP4A1 and 4C1 
when compared to human hepatocytes. Treatment of HepG2 cells with Aza-dC 
increased OATP2A1 and 5A1 mRNA expression to the level in hepatocytes, 
indicating that hypermethylation inhibits their expression. Distinct regulation of OATP 
expression in primary and metastatic hepatic tumors may alter uptake of drugs, 
hormones and prostaglandins, thereby influencing the efficacy of a given therapy. 
 
Running title: Altered OATP expression in liver cancer 
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INTRODUCTION 
Eleven members of the organic anion transporter family (OATP-family) have been 
identified in humans so far. They represent a group of sodium-independent 
transmembrane transporters for a broad spectrum of substrates, including hormones 
and their conjugates, prostaglandins, xenobiotics, and therapeutic drugs.1 Although 
the majority of human OATPs show wide tissue distribution, some members exhibit 
unique expression in distinct organs. The best studied of these are the “liver–specific” 
members OATP1B12,3 and 1B3.4 These OATPs are located in the basolateral 
membrane of hepatocytes where they mediate the uptake of endogenous substrates 
and drugs into the cell and play a critical role in the first step of the elimination 
process through the liver.5,6,7 In addition to OATP1B1 and 1B3, expression of the 
OATPs OATP1A2,8 2A1,9 2B1, 3A1 and 4A110 was first investigated by Northern 
blotting and conventional PCR analysis, and in more recent studies, by real-time RT-
PCR in normal liver.11,12 While robust expression of OATP1A2 and low levels of 
OATP3A1 and 4A1 mRNA were consistently reported, OATP2A1 was detected only 
by Northern blotting9 but not by conventional PCR analysis.10 
Investigations of OATP protein levels in liver are only available for a limited number 
of OATPs. Immunohistochemical studies showed that OATP1B1, 1B3 and OATP2B1 
are located in hepatocytes,2,3,4,13 and OATP1A2 was detected in bile duct cells 
(cholangiocytes).14 
It is known that expression of some OATPs such as OATP1B3 is altered by 
malignant transformation of cells. In addition, confined expression to specific organs 
as seen in normal tissue can be lost.1 In a recent study from our lab, we show that 
OATP2B1, 3A1 and 4A1 are differently expressed in breast cancer as compared to 
non-malignant tissue.15 Similarly, differences in OATP mRNA expression are also 
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seen for primary and metastatic bone tumors,16 and a number of OATPs such as 
OATP1A2, 1C1, 2B1 and 4A1 are expressed in human gliomas.17 
For liver cancers, studies have mainly focused on the two liver-specific OATP family 
members, OATP1B1 and 1B3.18,19 These transporters are down-regulated in the 
hepatoma cell line HepG220,11 and in liver cancer (hepatocellular carcinoma).19 
However, expression of other OATPs such as the prostaglandin transporter 
OATP2A1, the ubiquitously expressed OATP4A1, and the less characterized 
OATP5A1 has not been investigated in liver tumors as of yet.1 
As OATPs regulate the uptake of metabolites, drugs, and xenobiotics, expression of 
OATPs in malignant liver disease may influence tumor progression as well as the 
response to chemotherapeutic interventions. Therefore, we investigated the 
presence of all eleven OATP family members in primary and metastatic liver tumors 
using paired cancerous and non-cancerous samples from 22 patients with the 
primary liver cancers hepatocellular carcinoma (HCC) and cholangiocarcinoma 
(CCC) and metastases of solid tumors (MLT), the most frequent tumors in the liver.21 
Additionally, we assessed OATP mRNA expression in HepG2 cells treated with the 
demethylating agent 5-aza-2´-deoxycytidine (Aza-dC) and compared it to that of 
hepatocytes derived from nine human donors.  
Differential expression of individual OATPs in cancerous and normal liver might alter 
the uptake of signaling molecules including hormones, prostaglandins and anticancer 
drugs into hepatic cells, thus affecting the proliferation of tumor cells. 
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RESULTS 
OATP mRNA expression in human malignant and non-malignant liver 
samples. To study possible changes in the expression pattern of all human OATPs 
in hepatic malignancies, paired cancerous (HCC (n=7), CCC (n= 5) and MLT (n=10)) 
and adjacent non-cancerous samples were analyzed for mRNA expression of all 
known human OATPs using real-time RT-PCR.  
The OATP mRNA expression profile is depicted as a heat map in Figure 1, showing 
a cluster of non-cancerous (“normal”) and of cancerous samples with distinct 
expression of OATPs. Exceptions were seen for HCC samples #1 and #17 and 
sample #2 from the non-cancerous part of an MLT, which fit into the normal and 
cancer clusters, respectively.  
Decreased mRNA expression in most cancerous samples was observed for the liver-
specific transporters OATP1B1 and 1B3, and other OATPs, OATP2B1, 1A2 and 4C1. 
However, expression of OATP2A1, 3A1 and 4A1 and the less characterized 
OATP5A1 was increased in most of the malignant samples as compared to the non-
cancerous specimens. OATP1C1 and OATP6A1 mRNA levels were below the 
detection limit in all but three samples, which showed only marginal levels of these 
transporters. 
Further analysis revealed relative quantitative differences in OATP levels between 
the HCC, CCC and MLT groups (Figure 2). Remarkably, OATP1B1, showed a 44- 
and 36-fold decrease in CCC and MLT, respectively. Pronounced reduction of 1A2 
and 1B3 was also observed in the CCC group (113- and 75-fold, respectively). 
Decreases in OATP1B1 mRNA levels in HCC and OATP1B3 in HCC and MLT 
samples were moderate, up to 4-fold (p<0.05). Reduced expression was also seen 
for OATP2B1 in the CCC and MLT groups (4- to 7-fold).  
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In contrast, an up to 34-fold increase was seen for OATP2A1, 3A1 and 5A1 mRNA 
expression in HCC, CCC and MLT samples. Interestingly, a 20-fold upregulation was 
observed for OATP4A1 in the MLT group, while levels in HCC and CCC did not differ 
compared to the nonmalignant controls. This may be related to an upregulation in 
OATP4A1 expression in colon cancer as suggested from previous array data22 and in 
our control samples (6-fold upregulation, n=24, data not shown). Expression of 
OATP4C1 mRNA was highly variable but similar to that in the non-cancerous 
samples. 
Analysis of cellular localization of OATP2A1, 4A1 and 5A1 by 
immunofluorescence. Localization of OATP2A1, 4A1 and 5A1, which have not 
been previously studied at the protein level in hepatic tumors, were analyzed by 
immunofluorescence staining for their cellular localization on cryosections of tumors. 
In accordance with the real-time RT-PCR results, immunofluorescent staining of 
OATP2A1 was more intense in the cancerous samples than in the non-cancerous 
controls. However, OAT2A1 staining was rather diffuse in the cytoplasm of liver 
parenchymal cells, and mostly membranous staining was visible in the cancer 
section, suggesting activation of the transporter in these tumors (Figure 3A). 
Only background fluorescence was observed in hepatocytes in the non-cancerous 
HCC and MLT samples with anti-OATP5A1 and 4A1 antibodies, respectively (Figure 
3A). In the cancerous sections, OATP5A1 and 4A1 staining is clearly membrane 
associated. 
To investigate whether OATP2A1, 4A1 and 5A1 may also be expressed in cells 
deriving from proliferating bile ducts, we performed double staining with cytokeratin 
19 (CK-19) as a marker for biliary/progenitor cells.23 Remarkably, while OATP2A1 
and 4A1 is clearly co-localized with CK-19 immunofluorescence in cells surrounding 
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the bile ducts, OATP5A1 staining is barely apparent in CK-19 positive cells. 
Representative HCC and MLT samples are shown in Figure 3B and C, respectively. 
OATP mRNA expression in human hepatocytes and HepG2 cells. As 
HepG2 cells are a widely used model for the study of liver cancer, we also 
investigated the OATP mRNA expression pattern in this cell line (Figure 5) and 
compared it to that in human hepatocytes derived from nine human donors (Figure 
4). mRNA expression of eight OATPs (OATP1B1, 1B3, 2A1, 2B1, 3A1, 4A1, 4C1 and 
5A1) was observed in all hepatocyte samples and HepG2 cells. OATP1A2 was 
detectable in only one hepatocyte sample, but not in HepG2 cells. 
In hepatocytes, interindividual variations for OATP1B3, 2B1, 4C1 and 5A1 comprised 
a rather small range of 2-fold, but expression of OATP2A1, 3A1, and 4A1 mRNA 
varied considerably. Expression levels ranged from nearly undetectable to 9-fold for 
OATP2A1, 4-fold for OATP3A1 and 6-fold for OATP4A1. 
In HepG2 cells, pronounced downregulation by was seen for OATP1B1, 1B3, and 
5A1 mRNA expression compared to hepatocytes (p<0.05) (Figure 5). In addition, 
OATP2A1 and 3A1 mRNA levels were 11- and 43-fold lower, respectively, than the 
average expression in the hepatocytes. However, because of the high interindividual 
variability of these OATPs in hepatocytes (Figure 4), differences did not reach 
significance. OATP4A1 and 4C1 were the only OATPs that were expressed at higher 
levels in HepG2 cells than in human hepatocytes.  
To investigate whether downregulation of OATP mRNA might be due to 
hypermethylation in the promoter region, we analyzed changes in OATP expression 
after the treatment of HepG2 cells with the demethylating agent Aza-dC (Figure 5). 
Expression of OATP2A1 and 5A1 mRNA was vastly increased, and their expression 
reached levels similar to that observed in hepatocytes (OATP5A1: 1.1.0±0.16 and 
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OATP2A1: 2.54±1.05; Means±SEM). Interestingly, mRNA expression of OATP4A1 
and 4C1 in the HepG2 cells was decreased after Aza-dC treatment.  
 
DISCUSSION 
We show that of the eleven human OATPs, all but OATP1C1 and OATP6A1 are 
expressed in human cancerous and non-cancerous liver samples. With the exception 
of OATP1A2, these transporters are also detectable in hepatocytes and HepG2 cells. 
However, the expression patterns differ between non-cancerous samples and HCC, 
CCC and MLT specimens. Previous data demonstrated decreased expression of 
OATP1B1 and 1B3 in benign hyperplasia and malignant hepatocellular lesions as 
compared to normal liver,18,19,24 indeed, we also show different degrees of down-
regulation of these transporters in HCC, CCC and MLT as compared to non-
cancerous adjacent tissue. The most pronounced reduction in OATP1B1 and 1B3 
mRNA expression was observed in CCC and may at least partly reflect replacement 
of hepatocytes by malignant cells transformed from cholangiocytes and their 
precursors. Dedifferentiation of these cells may also explain downregulation of 
OATP1A2, a transporter expressed in cholangiocytes in healthy human liver.25 
We further show that expression of OATP2A1, 3A1, 4A1 and 5A1, an OATP with an 
unknown function,1 are detectable in most non-cancerous liver specimens. This was 
also seen in isolated normal hepatocytes, although the expression of OATP5A1 was 
highly variable between individuals. High interindividual variability may also explain 
why the expression of OATP2A1, 3A1 and 4A1 was not consistently observed in all 
studies of human liver using RNA from different sources.10,11,12 
Overall, our real-time RT-PCR data clearly show that in all tumor groups, OATP2A1, 
3A1 and 5A1 are expressed at higher levels in cancer versus non-cancerous tissues. 
Furthermore, increased mRNA levels of OATP2A1 correlated with a clear 
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membrane-located staining of cancer cells in HCC and MLT samples. Additionally, 
an overlapping pattern with the biliary/progenitor cell marker cytokeratin 1926 was 
observed in CCC and MLT. Similar to colon cancer, the prostaglandin transporter 
OATP2A1 may also be important in the termination of prostaglandin signaling in liver 
cancer.27,28 In addition, immunofluorescent staining of OATP4A1 and 5A1 was 
detected on the cell membranes in cancerous sections. However, bile duct derived 
cytokeratin 19-positive cells were only positive for OATP4A1. This is interesting, as 
expression of this cytokeratin is associated with a poor prognosis in liver cancer.29 In 
addition, we observed higher mRNA and protein expression of OATP4A1 only in the 
MLT group. This may reflect up-regulation of OATP4A1 mRNA in samples isolated 
from colon tumors, confirming previous array data.22 This would warrant further 
investigations of OATP4A1 as a possible diagnostic marker for colon carcinoma 
derived MLTs. 
We further demonstrate that all OATPs expressed in hepatic tumors, except 
OATP1A2, are also present in HepG2 cells. However, expression of most OATPs 
was downregulated in the hepatoma cell line. Epigenetic silencing of OATP 
expression may be important for the regulation of the expression of some OATPs. 
Indeed, this was recently demonstrated for OATP1B3 in HepG2 cells30 and for 
OATP2A1 in the colon cancer cell lines HT-29 and LS174.28 In line with these 
findings, we showed that Aza-dC effectively restored OATP2A1 and 5A1 mRNA 
expression in HepG2 cells to levels similar to those observed in hepatocytes.  
In conclusion, we show that in contrast to the “liver-specific” OATP1B1 and 1B3, 
mRNA expression of OATP2A1 and 5A1 is upregulated in primary and secondary 
hepatic tumors. Moreover, OATP4A1 mRNA upregulation is restricted to the MLT 
group. The distinct patterns and an epigenetic regulation for individual OATPs 
suggest specific functions for these factors in tumor cells, which may involve 
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transport of molecules important for cellular signaling as well as drugs used in 
therapy.  
 
PATIENTS AND METHODS 
Patient samples. Samples of liver cancer and the adjacent non-cancerous tissue 
were obtained from patients undergoing routine surgery for liver tumors. Informed 
consent was obtained from all patients and permission for the study was obtained 
from the Ethical Committee of the Institution.  
Hospital tumor history records were used to obtain information regarding stage at 
diagnosis, tumor grade and age. The total number of tumor specimens was 22 with a 
nearly equal gender distribution of ten male (n=10) and twelve (n=12) female 
samples. Twelve of the specimens were collected from HCC (n=7), CCC (n=5) and 
MLT (n=10) patients. Eight metastases were from patients with a primary tumor in the 
colon with the remainder of the primary tumors unknown. Detailed patient 
characteristics are shown in Table 1.  
Human hepatocytes. Expression of OATPs in hepatocytes from nine individuals 
was studied using real-time RT-PCR. Two females and seven males with a mean 
age of 50.9±11.8 (S.D.) years served as liver donors. Hepatocytes were isolated as 
described previously.31 
Cell culture (HepG2 cell line). The HepG2 cell line was originally obtained from 
ATCC and was maintained in phenol-red free RPMI 1640 medium (PAN Biotech, 
Aidenbach, Germany) containing 10% heat-inactivated fetal bovine serum (FBS) and 
antibiotics (100 U of penicillin/ml and 100 µg of streptomycin/ml; Invitrogen, Paisley, 
United Kingdom) in a humidified atmosphere at 37°C with 5% CO2/ 95% humidity. 
5-aza-2´-deoxycytidine (Aza-dC) treatment. HepG2 cells were seeded in 6-well 
plates. After 24 h incubation in serum-free medium, cells were treated with either 5 
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µM Aza-dC (Sigma, Deissenkirchen, Germany) dissolved in medium containing 0.1% 
DMSO or medium containing 0.1% DMSO only. After 72 h of treatment, total RNA 
from cells was isolated as described below. 
RNA extraction. Total RNA was extracted from liver tissue and cell lines using 
TRI Reagent® (Applied Biosystems, Warrington, UK) according to the manufacturer’s 
instructions. The concentration, purity, and integrity of RNA samples were 
determined by UV absorbance and electrophoresis. RNA from cancerous and non-
cancerous colon samples was a kind gift from Dr. E. Kallay.32 
Quantitative real-time RT-PCR. We reverse transcribed 2 µg of total RNA to 
cDNA using the high capacity cDNA reverse transcription Kit (Applied Biosystems) 
using random hexamer primers as recommended by the manufacturer. We 
purchased TaqMan® Gene Expression Assays (Applied Biosystems) for all eleven 
human OATPs. In order to evaluate the appropriate reference genes, we analyzed 
the expression of 12 different human housekeeping genes in malignant and adjacent 
non-malignant tissue samples using a geNormTM housekeeping gene selection kit 
with PerfectProbeTM (PrimerDesign Ltd., South-Hampton, UK). We selected CYC1, 
UBC, ATP5B and 18S as acceptable reference genes for TaqMan® real-time analysis 
of the tissue samples. For the human hepatocytes and HepG2 cells, we tested a 
panel of eight housekeeping genes and HPRT was chosen as the acceptable 
reference gene. Real-time RT-PCR was performed in a reaction volume of 10 µl. The 
target gene amplification mixture contained 5 µl 2X TaqMan® Gene Expression PCR 
Master Mix, 0.5 µl of the appropriate Gene Expression Assay, 10 ng template cDNA 
diluted in 2.5 µl nuclease free water and 2 µl nuclease free water. Thermal cycling 
conditions were as follows: 2 min at 50°C, 10 min at 95°C, 40 cycles of 15 s at 95°C 
and 1 min at 60°C. Fluorescence generation from TaqMan® probe cleavage by the 
5’→3’ exonuclease activity of the DNA polymerase was measured with the 
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StepOnePlus system (Applied Biosystems). All samples were amplified in duplicates. 
Results were imported into Microsoft Excel for further analysis and comparable cDNA 
amounts in the experimental samples were calculated according to Hellemans et al.33 
Real-time RT-PCR was performed with the following prefabricated TaqMan® Gene 
Expression Assays (Applied Biosystems) containing intron-spanning primers: 
OATP1A2: Hs00245360_m1, OATP1B1: Hs00272374_m1, OATP1B3: 
Hs00251986_m1, OATP1C1: Hs00213714_m1, OATP2A1: Hs00194554_m1, 
OATP2B1: Hs00200670_m1, OATP3A1: Hs00203184_m1, OATP4A1: 
Hs00249583_m1, OATP4C1: Hs00698884_m1, OATP5A1: Hs00229597_m1, 
OATP6A1: Hs00542846_m1 and the endogenous controls 18S Part # 4310893E 
(Applied Biosystems), HPRT Part # 4310890E (Applied Biosystems), CYC1, UBC 
and ATP5B (HK-DD-hu-300, Primer Design Ltd.). 
Real-time RT-PCR data analysis. Real-time RT-PCR data are presented as a 
heat map with hierarchical clustering analysis using average linkage algorithms and 
distance measures based on standard Pearson correlation (centered correlation). 
Immunofluorescence. For immunofluorescence staining, 4 µm sections were 
generated with a Cryostat-Microtome HM 500 OM (Microm, Heidelberg, Germany) 
from frozen liver samples (stored at -80°C). Tissue sections were fixed with acetone 
and blocking was performed with 5% BSA in PBS. Incubation with the primary 
antibody was done overnight. Dilutions for primary antibodies were 1:100 for 
OATP2A1 (ab160200, Cayman Chemical, Ann Arbor, MI) and OATP5A1 (HPA 
025062, Atlas Antibodies, Stockholm, Sweden), 1:20 for OATP4A1 (sc-51169, Santa 
Cruz Biotechnology, CA), and 1:500 for cytokeratin 19 (clone A53-B/A2.26, Lab 
Vision-Neo Markers, Fremont, CA, USA). After washing, sections were incubated 
with Alexa Fluor® IgG (Invitrogen, Carlsbad, CA) using the following dilutions: Alexa 
Fluor® 488 anti-rabbit IgG (1:2000) and anti-goat IgG (1:200), and Alexa Fluor® 568 
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anti-mouse IgG (1:1000). Cell nuclei were counterstained with bisbenzimide in PBS 
(Hoechst 33342, Sigma, Munich, Germany) at a 1:5000 dilution. Sections were 
mounted in Mowiol 4-88 (Carl Roth, Karlsruhe, Germany) and fluorescent staining 
was visualized with an Axioplan 2 microscope (Carl Zeiss, Jena, Germany). Images 
were captured using an AxioCam HRc2 Color CCD digital camera and Axiovision 4.6 
software (Carl Zeiss Vision GmbH, Aalen, Germany). 
Statistical analyses. Comparisons of significant differences in the expression of 
OATPs between cancerous and adjacent non-cancerous tissue specimens were 
performed using the Mann-Whitney U test. Significance was defined as p<0.05. 
OATP nomenclature. Official nomenclature differs between genes and protein 
using the terms SLCO and OATP, respectively.34 To facilitate understanding, OATP 
was used for both genes and proteins. 
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FIGURE LEGENDS 
Figure 1. Heatmap showing mRNA expression of all 11 human OATPs in non-
cancerous (N) and cancerous (T) liver tissue samples of 22 patients. Data 
represent upregulation (red) or downregulation (green) of OATP mRNA compared to 
the median expression level (black) of all samples.  
 
Figure 2. mRNA expression of human OATPs in different types of liver cancer 
compared to the non-cancerous controls. Data represent the logarithmic fold 
regulation of mRNA in the cancerous samples compared to the adjacent non-
cancerous ones. Data are given as means±SEM. HCC, hepatocellular carcinoma; 
CCC, cholangiocarcinomas; MLT, metastatic liver tumors of the colon. Asterisks 
indicate statistical significance (p<0.05). 
 
Figure 3. Immunolocalization of OATP2A1, 4A1 and 5A1 in liver cancer.  
A Immunofluorescence staining of tissue sections from non-cancerous and adjacent 
cancerous sections  were probed with antibodies against OATP2A1, 4A1 and 5A1.  
(inserts without nuclei staining). Preferential green staining of plasma membranes is 
seen in the cancerous sections, only.  
B Double immunofluorescence staining of OATP2A1 and 5A1 (green) with the 
biliary/progenitor cell marker cytokeratin 19 (red) and the merged OATP/CK-19 
image in an HCC sample. 
C Double immunofluorescence staining of OATP2A1 and 4A1 (green) with the 
biliary/progenitor cell marker cytokeratin 19 (red) and the merged OATP/CK-19 in an 
MLT sample. 
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Figure 4. Expression of OATPs in human hepatocytes. Total RNA was isolated 
and reverse transcribed from hepatocytes prepared from livers of nine healthy 
individuals. OATP mRNA expression was then investigated by real-time RT-PCR 
analysis. Values from each of the seven analyzed hepatocyte populations are 
indicated. Line, mean of the mRNA values from the nine hepatocyte donors. 
 
Figure 5. Expression of OATP mRNAs in HepG2 cells and restoration of 
OATP2A1 and 5A1 mRNA expression after Aza-dC treatment. Total RNA was 
isolated and reverse transcribed from HepG2 cells either treated with solvent (0.1% 
DMSO) or with 5 µM 5-Aza-2’-deoxycytidine for 72 h. mRNA expression levels of 
individual OATPs are given as the logarithmic fold regulation of mRNA in the HepG2 
cells compared to the human hepatocytes. Data are given as means±SEMs. 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Statement of Translational Relevance:  
The identification of markers for the progression and chemotherapy resistance of 
ovarian cancer is of high interest. OATPs/SLCOs proteins are capable of transporting 
a broad range of endogenous compounds including prostaglandins, steroid 
conjugates as well as anticancer drugs and were found to have relevance as cancer 
progression markers and in drug resistance. However, investigations of SLCO 
expression in malignant disease of the ovaries were restricted to ovarian cancer cell 
lines. In the present study, we systematically investigated the mRNA distribution of all 
11 human SLCO and of four ABC-transporter genes, known to influence drug 
resistance in malignant disease, in a panel of 191 specimens of ovarian carcinomas. 
Indeed, we could show significant associations of SLCO3A1 with FIGO staging and 
of SLCO6A1 with the patients’ outcome prompting further investigations on the role 
of SLCO3A1 and SLCO6A1 in the progression and chemotherapy resistance of 
ovarian cancer.  
 
Abstract 
Ovarian cancer has a poor prognosis as it is generally diagnosed at an advanced 
stage and tumors are often resistant to standard chemotherapy regimens. While the 
role of ABC-efflux transporters in chemoresistance of ovarian cancer is well 
established, data on OATP/SLCO drug uptake transporters in ovarian cancer are 
greatly missing.  Therefore, we characterized the mRNA expression profiles of all 
SLCO family members together with four ABC-pumps related to anticancer drug 
resistance (ABCB1/P-glycoprotein, ABCC2/MRP2, ABCC3/MRP3, ABCB2/TAP1) in 
specimens from 191 ovarian cancer patients and correlated their expression pattern 
to clinicopathological parameters of the patients. SLCO3A1 levels showed 
differences in FIGO stage (P = 0.03) and might be a marker for tumor progression. 
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Additionally, higher ABCB2 levels were associated with a decreased residual tumor 
load (P = 0.015). In the univariate survival analysis, increased ABCB2 expression 
was associated with a significantly lower relative risk of receiving a relapse (P = 
0.005). Moreover, expression of SLCO6A1, ABCB2 and ABCC2; minimal residual 
disease, FIGO stage and tumor grade, were found to be associated with the relative 
risk for relapse using a multivariate Cox proportional hazard model. The obtained 
predictor values were dichotomized (25 % percentile) for identifying a low and high 
risk group with significant differences in the disease free survival (P < 0.0001) and 
overall survival (P = 0.012). This is the first report showing SLCO transporters 
together with ABC-efflux pumps as potential markers in ovarian cancer.  
 
Introduction 
Ovarian cancer is generally diagnosed at an advanced stage as early symptoms are 
inconspicuous and reliable diagnostic biomarkers are not available [DiSAIA et al., 
2002]. This contributes to a poor 5 year overall survival rate of < 40% and a high 
death rate [PERMUTH-WEY & SELLERS, 2009]. After initial surgery on the tumor, 
standard chemotherapy with platinum derivatives and taxanes like paclitaxel 
[ROWINSKY & DONEHOWER, 1995] is applied. Although high response rates to this 
initial regimen are observed, a relapse is seen in two-thirds of patients due to the 
rapid development of drug resistance and this contributes to the overall poor survival 
[AGARWAL & KAYE, 2003]  [MARKMAN, 2008]. 
An important factor in the development of anti-cancer drug resistance is an 
insufficient intracellular accumulation of cytotoxic agents. It is well established that 
several ABC-transporters including MDR1/P-glycoprotein (P-gp) encoded by the 
ABCB1 gene [AMBUDKAR et al., 2003], MRP2 (ABCC2), MRP3 (ABCC3) are 
associated with chemoresistance in ovarian cancer by mediating the rapid efflux of 
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cytotoxic drugs [NANIWA et al., 2007; BAEKELANDT et al., 2000] [MATERNA et al., 
2004; SUROWIAK et al., 2006; O’BRIEN et al., 2008]. In addition, TAP1 and TAP2 
coded by the ABCB2 and ABCB3 gene, respectively, are involved in the major 
histocompatibility complex class I-restricted antigen processing machinery (APM), 
[LEHNER & CRESSWELL, 2004]. Indeed, ABCB3 was found to be down-regulated 
in ovarian cancer at the mRNA level [AUNER et al., 2010]. Furthermore, it was 
suggested that TAP may contribute to MDR, in particular in cells overexpressing 
MRPs [IZQUIERDO et al., 1996].  
Besides efflux, uptake into the cells is also important to determine intracellular drug 
concentration [CVETKOVIC et al., 1999]. One of the most important group of 
transport proteins is the organic anion transporting polypeptide family/solute liquid 
carriers (OATP/SLCO), which are highly expressed in tissues such as liver, intestine, 
kidney, brain, and breast and in various tumors and are candidates for anticancer 
drug uptake transporters [HAGENBUCH & GUI, 2008]. OATPs are capable of 
transporting a broad range of endogenous, amphipathic organic compounds 
including bile salts, thyroid hormones, prostaglandins, steroid conjugates, as well as 
anticancer drugs. Therefore, they play an important role in drug absorption, 
disposition and excretion [KIM RB, 2003; MIKKAICHI et al., 2004] 
To date, 11 OATP/SLCO members grouped according to their amino acid homology 
in the OATP families 1-6, have been identified in various normal and tumorous 
tissues [HAGENBUCH & MEIER, 2004]. For example, high expression levels for 
SLCO1B3, mediating cellular uptake of paclitaxel [SMITH et al., 2005], were detected 
in tumors of the gastrointestinal tract, and breast cancer, while SLCO6A1, originally 
identified as a testis specific antigen, was found to be expressed in lung tumors [ABE 
et al., 2001; MUTO et al., 2007; LEE et al., 2004]. Thus far, in ovarian cancer, data 
on the expression of individual SLCOs are still limited. SLCO2A1, SLCO3A1, and 
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SLCO4A1 were first detected by Tamai and coworkers in the ovary and ovarian 
cancer cell lines by conventional RT-PCR [TAMAI et al, 2000]. Later, expression of 
various SLCOs, including SLCO5A1, was confirmed by real-time PCR in normal 
ovary and ovarian cancer cell lines of the NCI-60 panel [OKABE et al., 2008].  
This could be important as some SLCOs are discussed as markers for tumor 
progression e.g. SLCO1B3 in breast cancer and SLCO1B3 and SLCO4A1 in colon 
cancer [MUTO et al., 2007; LEE et al., 2008; ANCONA et al., 2006].  
To gain further insight into the possible role of membrane transporters in ovarian 
cancer, we characterized the mRNA expression profiles of all 11 known transporters 
of the OATP/SLCO families 1-6, and of four members from the ABC family known to 
be involved in drug resistance in specimens from 191 patients with ovarian cancer. 
The expression pattern of the transporters was then correlated to patients’ survival. 
 
Materials and Methods 
 
Patients 
A total of 191 patients were included into the present multicenter study (Department 
of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, Austria: n = 
7; Department of Obstetrics and Gynecology, Charité/Campus Virchow-Klinikum, 
University Medicine of Berlin, Berlin, Germany: n = 71; Institute of Tumorbiology, 
University Clinic Hamburg-Eppendorf, Hamburg, Germany: n = 30; Division of 
Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium: n = 61; 
Department of Obstetrics and Gynecology, Medical University Vienna, Vienna, 
Austria: n = 22). The tumor samples were collected in the course of the EU-project 
Ovarian Cancer Diagnosis (OVCAD, www.ovcad.eu, 2006-2010). Informed consent 
for the scientific use of biological material was obtained from all patients in 
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accordance to the requirements of the ethical committee of the individual institutions. 
Clinicopathological parameters of the patients are displayed in Table 1.  
 
RNA extraction 
Total RNA was isolated using the ABI 1600 nucleic acid prepstation (Applied 
Biosystems, Foster City, CA, USA) following the instructions of the manufacturer. 
Shortly, 20 – 30 mg of frozen tissue were pulverized using a micro-dismembrator (B. 
Braun Biotech International, Melsungen, Germany). The obtained tissue powder was 
dissolved in 1 ml of provided lysis solution. Thereafter, the specimens were digested 
with 10 µl proteinase K / ml of lysate for one hour at room temperature followed by 
RNA isolation using the ABI 1600 nucleic acid prep station including a DNase I 
digestion protocol. The eluted RNA was precipitated with sodium acetate and 100 % 
ethanol at -20 °C overnight. The RNA pellet was washed with 70 % ethanol, dried, 
and resuspended in nuclease free water. The integrity of the total RNA was 
confirmed by lab-on-a-chip technology using an Agilent 2100 Bioanalyzer (Agilent 
Technologies Inc., Santa Clara, CA, USA). The RNA concentration was assessed 
using a spectrophotometer.  
 
Reverse Transcription and real-time RT-PCR 
We reverse transcribed 1 µg of total RNA in 20 µl reactions using the High Capacity 
cDNA RT kit (Applied Biosystems) with the provided random primers and RNase 
inhibitor (PN N808-0119, Applied Biosystems) according to the instructions of the 
manufacturer. The reverse transcription mix contained 2 µl of 10x RT buffer, 0.8 µl of 
25x dNTP mix (100mM), 2 µl 10x random primer mix, 1 µl RNase inhibitor, 1µl 
Multiscribe™ reverse transcriptase, 1 µg total RNA in nuclease-free water and 
nuclease-free water was added to a final volume of 20 µl. The thermal cycling 
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program for the reverse transcription reaction was 10 min 25°C, 120 min 37°C, and 5 
s 85°C using a MyCycler™ thermocycler (Bio-Rad, Hercules, CA, USA). As it has 
been shown in the past, the choice of reference genes as internal normalization 
factors can have a profound effect on the experimental results in real-time RT-PCR 
[DHEDA, 2005]. For accurate normalization of mRNA between ovarian cancer tissue 
specimens we determined ACTB, TOP1, UBC, and YWHAZ out of a panel of 12 
housekeeping genes (the others: 18S, ATP5B, B2M, CYC1, EIF4A2, GAPDH, 
RPL13A, SDHA) as appropriate reference genes in specimens from ovarian cancer 
patients using a geNorm kit (PrimerDesign Ltd., Southampton, UK) and the geNorm 
software [VANDESOMPELE et al., 2002; VANDESOMPELE et al., 2004]. Gene 
expression assays (Applied Biosystems, Foster City, CA) were purchased for all 11 
human SLCOs and the four ABC transporter genes (Table 2). The endogenous 
control assay for ACTB (PN 4326315E, Genbank Acc. No. NM_001101.2) was 
obtained from Applied Biosystems and prefabricated hydrolysis probe assays for the 
endogenous control genes TOP1 (Genbank Acc. No. NM_003286), UBC (Genbank 
Acc. No. NM_021009), and YWHAZ (Genbank Acc. No. NM_003406) were 
purchased from PrimerDesign Ltd. Real-time RT-PCR using hydrolysis probes was 
performed in an amplification mixture of 10 µl containing 5 µl 2x TaqMan® Gene 
Expression Master Mix (Applied Biosystems), 0.5 µl of the appropriate Gene 
Expression Assay, 5 ng template cDNA diluted in 4 µl nuclease free water, and 0.5 µl 
nuclease free water. Thermal cycling conditions were 10 min at 95 °C followed by 40 
cycles of 15 s at 95 °C and 1 min at 60 °C. Fluorescence generation due to 
hydrolysis probe cleavage was measured with the ABI 7900HT Fast real-time PCR 
system equipped with SDS 2.3 software (Applied Biosystems). The real-time RT-
PCR reactions were carried out in duplicates using 96 well format plates (Applied 
Biosystems) and adhesive optical films (Applied Biosystems). Since the total number 
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of samples exceeded the number of samples that could be analyzed during a single 
run the samples had to be split on multiple plates and a qPCR reference total RNA 
(Cat. No. 636690, Clontech Laboratories Inc., Mountain View, CA, USA) was used as 
an inter-run calibrator (IRC) to compensate between plates for technical inter-run 
variations. The IRC was analyzed in quadruplicates on every plate. Raw Ct values 
were exported into Microsoft Excel and results were calculated using the ∆∆Ct 
method [LIVAK & SCHMITTGEN, 2001] as relative quantities (RQ) normalized to the 
geometric mean of the four endogenous control genes [VANDESOMPELE et al., 
2002] and with the IRC assigned as calibrator. For the statistical analysis we 
transformed the obtained RQ values by log2(RQ). 
 
Statistical Analysis 
In order to compare SLCO- and ABC-transporter expression between two or more 
groups a T-test or one-way ANOVA, respectively, was performed using the log2-
transformed RQ value as independent variable. The potential influence of SLCO- and 
ABC-transporter expression on disease free and overall survival is presented in plots 
of the corresponding Kaplan-Meier estimates and quantified using the Cox 
proportional hazards regression model. OVCAD criteria were used to define time 
points for disease progression. Univariate Cox estimates were used to approximate 
the influence of known prognostic factors and the potential new prognostic factors. 
The final Cox regression model including clinical parameters and candidate genes 
with relative risk < 0.95 and > 1.05 was built using the backward conditional 
procedure (the removal term was set to 0.1). All statistical analysis was performed 
with the IBM SPSS statistical package for PC (version 18.0; SPSS Inc., an IBM 
company, Chicago, IL, USA). Multiple-testing correction was done by the Bonferroni-
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Holm procedure. Two-sided P-values ≤ 0.05 were considered as statistically 
significant. 
 
 
Results 
 
Expression of SLCO- and ABC-transporters in ovarian carcinoma 
The investigation of SLCO and ABC mRNA in specimens from 191 patients with 
ovarian carcinoma was done using real-time RT-PCR and is displayed as foldmean up- 
or down-regulation together with the lowest (foldmin) and highest (foldmax) observed 
values compared to a commercially available reference RNA (Clontech) (Table 3). 
Consistent expression in all samples was seen for five SLCOs (SLCO2A1, 
SLCO2B1, SLCO3A1, SLCO4A1 and SLCO5A1) and all investigated ABC-
transporters. Significant expression of SLCO1A2, SLCO1B1, SLCO1B3, SLCO1C1, 
SLCO4C1 and SLCO6A1 could only be detected in subsets of samples. 
 
Significant relationships of SLCO3A1 and ABCB2 tumor expression with 
clinicopathologic parameters. 
Using one-way ANOVA with log2-transformed RQ values as independent variable we 
found that the expression of the SLCO3A1 gene, coding for the OATP3A1 uptake 
transporter, was significantly (P = 0.030) different in tumors with FIGO stage II (n = 9, 
RQmean = 0.18), III (n = 151, RQmean = 0.33) and stage IV (n = 30, RQmean = 0.39) 
(Figure 1 and Table 4). Furthermore, a significant connection between the expression 
of the ABCB2 gene and the presence of residual tumor mass was observed. We 
detected higher ABCB2 expression in tumors of patients where complete tumor 
resection was possible (n = 90, RQmean = 1.04 RQ) compared to patients with 
postoperative tumor mass (n = 96, RQmean = 0.70, P = 0.015) after debulking surgery 
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was performed (Figure 2 and Table 4). No other statistical significant relationships 
were observed between SLCO- or ABC-transporter gene expression concerning 
patients’ age, FIGO stage, grade, histology, or residual tumor load.  
 
Influence of SLCO6A1, ABCB2, and ABCC2 on disease free survival and overall 
survival. 
Univariate survival analysis revealed that higher ABCB2 levels (P = 0.005) were 
found to be statistically significant to identify patients with longer disease free 
survival. From all SLCO-transporters, only SLCO1B1 showed a tendency to improve 
disease free survival (P = 0.06). As expected, patients with lower FIGO stage (P = 
0.009), better grading (P = 0.01), and no residual disease (P = 0.004) had a better 
outcome regarding disease-free survival (Table 5). 
When all terms were analyzed by the multivariate Cox proportional hazard model in a 
backward elimination process, two parameters were predictive for a prolonged 
disease free survival, namely increased expression of the transporters SLCO6A1 
(RR = 0.90, P = 0.043), and ABCB2 (RR = 0.81, P = 0.004). Associated with 
decreased disease free survival was a higher FIGO stage (RR = 1.30, P = 0.026), 
higher tumor grading (RR = 1.57, P = 0.025), and ABCC2 transporter expression (RR 
= 1.20, P = 0.041) (Table 5). Residual disease, however, was not found to be 
statistically significant. The obtained predictor values were dichotomized at the 25 % 
percentile resulting in a low and high risk group with high significance in the disease 
free survival analysis (P < 0.0001, log-rank test) as shown in the corresponding 
Kaplan-Meier survival plot (Fig. 3). Additionally, a significant relationship was also 
observed in the overall survival analysis curve (P = 0.012, log-rank test) (Fig. 4). 
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Discussion 
In the present study, we systematically investigated the mRNA distribution of all 11 
human SLCO genes and of four ABC-transporter genes, known to influence drug 
resistance in malignant disease, in a panel of 191 specimens of ovarian carcinomas.  
Thus far, investigations of SLCO expression in malignant disease of the ovaries were 
restricted to ovarian cancer cell lines [TAMAI et al., 2000; OKABE et al., 2008]. We 
identified SLCO2A1, SLCO2B1, SLCO3A1, SLCO4A1, and SLCO5A1 genes to be 
ubiquitously expressed in carcinomas of the ovaries. mRNA expression of SLCO1A2, 
SLCO1B1, SLCO1B3, SLCO1C1, SLCO4C1, and SLCO6A1 was only detected in a 
limited number of tissue samples which expression levels did not correlate to any 
clinical parameters. These data are in accordance to previous studies also reporting 
aberrant expression of SLCOs in various cancer entities [ABE et al. 2001; MUTO et 
al., 2007; LEE et al., 2004; LEE et al. 2008]. 
We were able to show significantly different mRNA levels of the SLCO3A1 gene 
(coding for the OATP3A1 protein) in tumors classified as FIGO stage II, III and IV 
(one-way ANOVA, P = 0.03). SLCO3A1-specific anticancer drugs have not been 
described so far, but functional analysis in X. laevis oocytes identified thyroid 
hormones, peptides and prostaglandin as substrates for this transporter [ADACHI et 
al., 2003, HUBER et al. 2007]. At least for another prostaglandin-transporting SLCO, 
namely SLCO2A1, it was shown that it is important for the removal of prostaglandin 
E2 (PGE2) from the extracellular space where it acts via G-protein coupled plasma 
membrane receptors [BREYER et al., 2001]. After SLCO-mediated transport into the 
cytosol PGE2 is further inactivated via the intracellular 15-hydroxyprostaglandin 
dehydrogenase [NOMURA et al., 2004]. This could be important as PGE2 was shown 
to increase cell invasiveness in ovarian cancer cells [LAU et al., 2010]. Increased 
expression might be related to tumor metabolism and a decreased extracellular pH 
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caused by anaerobic glycolysis in hypoxic tumor cells may stimulate the OATP 
activity [LEUTHOLD et al., 2009]. This would be important as an acidic tumor 
environment promotes a more aggressive and invasive phenotype [ANNIBALDI & 
WITTMAN, 2010]. 
Interestingly, decreased mRNA levels of ABCB2/TAP1 demonstrated a significant 
association with the presence of residual tumor load (P = 0.015). These findings are 
in line with the observation that impaired antigen presentation can lead to 
immunoescape in cancers [YIGIT et al., 2010]. TAP1 is located on the membrane of 
the endoplasmic reticulum (ER) where it passages short peptides, generated by 
ubiquitin/proteasome-mediated degradation, from the cytoplasm into the ER lumen. 
Subsequently, the peptides are assembled on MHC class I-β2-microglubulin 
heterodimers which migrate to the cell membrane where they can be recognized by 
CD8+ T-cells [PROCKO & GAUDET, 2009].  
 
In our study, we found a significant beneficial influence of ABCB2 on the disease free 
survival by univariate as well as multivariate survival analysis supporting the findings 
of Han and coworkers where intact expression of APM components was strongly 
associated with prolonged survival of ovarian cancer patients [HAN et al., 2008].  
A beneficial factor for patients’ survival was also associated with increased 
expression of SLCO6A1. In healthy tissue, SLCO6A1 is predominately expressed in 
testis but not in ovary [SUZUKI et al., 2003, OKABE 2008]. However, it is aberrantly 
expressed in lung cancer, lung cancer cell lines as well as in samples from bladder, 
esophageal and brain tumors [LEE et al., 2004; OBA-SHINJO et al, 2007]. The 
frequent expression of OATP6A1 in tumors as cancer/testis surface antigen may 
allow this transporter to be a potential target for monoclonal antibodies therapy. As 
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no substrates of SLCO6A1 are known, further experiments have to clarify its role in 
physiology and cancerogenesis.  
In contrast, the expression of the drug efflux pump ABCC2 was significantly 
associated with an unfavorable prognosis in the multivariate Cox proportional hazard 
model. This is in line with the findings of Suroviak et al. (2006) who correlated 
nuclear membrane association of ABCC2 with resistance to cisplatin and clinical 
outcome in ovarian cancer [SUROWIAK et al., 2006]. Furthermore, Auner and 
coworkers could also demonstrate a significant difference in the expression of 
ABCC2 between primary and recurrent carcinoma indicating a possible role of 
ABCC2 as mediator of multiple drug resistance in ovarian carcinoma [AUNER et al., 
2010].  
In conclusion, we investigated for the first time the expression of all SLCO gene 
family members in a large cohort of ovarian carcinoma patients and report significant 
associations of SLCO3A1 with FIGO staging and of SLCO6A1 with the patients’ 
outcome prompting further investigations on the role of SLCO3A1 and SLCO6A1 in 
the progression and chemotherapy resistance of ovarian cancer.  
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Legends to the figures 
 
Figure 1 Box plot for the correlation of SLCO3A1 with FIGO stage. 
Expression levels of SLCO3A1 in ovarian tumor samples were plotted against the 
number of patients with FIGO stage II (n = 9), III (n = 151) and IV (n = 30). The box is 
bounded above and below by the 25 % and 75 % percentiles, the median is the line 
in the box. There is a significant difference between the three groups (FIGO stages II, 
III, and IV) by one-way ANOVA (P = 0.030). 
 
Figure 2 Box plot showing correlation of ABCB2 expression with residual 
disease. 
Expression of ABCB2 in ovarian cancer samples was plotted against number of 
patients with (n = 96) or without (n = 90) residual disease. The box is bounded above 
and below by the 25 % and 75 % percentiles, the median is the line in the box. A 
significant correlation of lower levels of ABCB2 (TAP1) and presence of residual 
disease was observed by T-test (P = 0.015). 
 
Figure 3 Kaplan-Meier survival curve for disease free survival (DFS). 
The predictor values for disease free survival obtained by the multivariate Cox 
regression model were dichotomized at the 25 % percentile resulting in a high and 
low risk group (P < 0.0001, log-rank test).  
 
Figure 4 Kaplan-Meier survival curve for overall survival.  
The predictor values for DFS obtained by the multivariate Cox regression model 
showed to be also predictive for the overall survival (P < 0.012, log-rank test). 
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Figure 2 
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Figure 3 
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Figure 4 
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Median         57 (26 -85)
Median         17 (1 - 48)
Number of recurrencies       121 (63.4)
Median         25 (1 - 49)
Number of deaths         53 (27.7)
Serous       169 (88.5)
Endometrioid           6 (3.1)
Mucinous           3 (1.6)
Mixed epithelial tumor           7 (3.7)
Undifferentiated carcinoma           6 (3.1)
II            9 (4.8)
III        151 (79.0)
IV          30 (15.7)
1            6 (3.1)
2          40 (20.9)
3        136 (71.3)
None          90 (47.2)
≤ 1cm          29 (15.1)
> 1cm          67 (35.1)
Adjuvant        147 (77.0)
Neoadjuvant          26 (13.6)
Intraperitoneal          18 (9.4)
Carboplatin and paclitaxel        137 (71.7)
Carboplatin and other         22 (11.5)
Carboplatin         13 (6.8)
Cisplatin and paclitaxel           8 (4.2)
Other         11 (5.8)
Responder       147 (77.0)
Non-Responder         44 (23.0)
Patients       191 (100.0%)
FIGO§ (1 [0.5%] missing)
Grading (9 [4.7%] missing)
Residual disease after initial surgery          
(5 [2.6%] missing)
Type of chemotherapy
Table 1. Clinicopathologic Parameters of Patients
§International Federation of Gynecologists & Obstetricians
Age at diagnosis [years]
Disease free survival [months]
Overall survival [months]
First line chemotherapy
Response to first-line chemotherapy
Histology
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Gene 
Symbol Assay IDa           
Amplicon 
size (bp)
Accession 
number
SLCO1A2 hs00245360_m 1 57 NM_134431.2 
NM_021094.2
SLCO1B1 hs00272374_m 1 77 NM_006446.3
SLCO1B3 hs00251986_m 1 69 NM_019844.2
SLCO1C1 hs00213714_m 1 92 NM_017435.3
SLCO2A1 hs00194554_m 1 87 NM_005630.1
SLCO2B1 hs00200670_m 1 113 NM_007256.2
SLCO3A1 hs00203184_m 1 89 NM_013272.2
SLCO4A1 hs00249583_m 1 80 NM_016354.3
SLCO4C1 hs00698884_m 1 77 NM_180991.4
SLCO5A1 hs00229597_m 1 60 NM_030958.1
SLCO6A1 hs00542846_m 1 63 NM_173488.3
ABCB1 hs00184500_m 1 67 NM_000927.3
ABCC2 hs00166123_m 1 75 NM_000392.3
ABCC3 hs00358656_m 1 98 NM_001144070.1 
NM_003786.3
ABCB2 hs00184465_m 1 61 NM_000593.5
Table 2.
 Gene Expression Assays  used for real-time RT-PCR            
(Applied Biosystems)
aApplied Biosystems
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Gene Name Foldmean Foldmin Foldmax
 SLCO1A2 -76.5 ND 2.2
 SLCO1B1 -55.1 ND 3.1
 SLCO1B3 -25.9 ND 40.2
 SLCO1C1 -286.4 ND -4.8
 SLCO2A1 -9.1 -64.4 5.7
 SLCO2B1 -3.5 -27.9 2.0
 SLCO3A1 -3.1 -21.9 1.7
 SLCO4A1 -4.3 -643.6 21.3
 SLCO4C1 -130.1 ND 1.6
 SLCO5A1 -5.4 -626.0 21.6
 SLCO6A1 -3014.2 ND 31.6
 ABCB1 -11.2 -100.4 2.9
 ABCB2 -1.2 -20.5 5.0
 ABCC2 -22.6 -188.7 2.2
 ABCC3 -2.4 -91.8 11.2
Table 3. SLCO- and ABC-Transporter Genes 
expressed in Ovarian Carcinoma‡
‡Indicated as fold up- or downregulation compared to human 
reference RNA (Clontech); ND, not detectable.
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N SLCO1A2 SLCO1B1 SLCO1B3 SLCO1C1 SLCO2A1 SLCO2B1 SLCO3A1 SLCO4A1 SLCO4C1 SLCO5A1 SLCO6A1 ABCB1 ABCB2 ABCC2 ABCC3
< 50 55 -6.87 -5.51 -4.02 -7.95 -3.17 -1.70 -1.51 -1.78 -7.75 -2.44 -11.68 -3.17 -0.09 -4.33 -1.05
> 50 136 -6.01 -5.90 -4.97 -8.25 -3.19 -1.83 -1.65 -2.22 -6.73 -2.45 -11.51 -3.61 -0.33 -4.57 -1.31
P = 1.000 0.663 1.000 1.000 1.000 1.000 1.000 1.000 0.420 0.993 1.000 0.405 1.000 1.000 1.000
II 9 -4.91 -4.68 -3.71 -8.02 -3.09 -1.97 -2.48 -2.80 -6.77 -3.25 -11.76 -3.64 0.03 -4.96 -1.55
II I 151 -6.21 -5.83 -4.58 -8.20 -3.25 -1.76 -1.59 -2.03 -7.08 -2.26 -11.40 -3.42 -0.25 -4.44 -1.17
IV 30 -6.73 -5.85 -5.42 -7.97 -2.87 -1.89 -1.37 -2.24 -6.92 -3.23 -12.22 -3.79 -0.35 -4.60 -1.35
P = 1.000 0.350 1.000 1.000 1.000 1.000 0.030 1.000 0.928 1.000 1.000 1.000 1.000 1.000 1.000
1 6 -8.38 -5.18 -3.26 -8.47 -3.26 -1.47 -1.67 -2.52 -9.08 -1.51 -10.92 -3.05 -1.03 -4.15 -0.11
2 40 -6.80 -5.75 -4.52 -8.25 -3.20 -1.86 -1.68 -2.17 -7.31 -2.79 -11.88 -3.01 -0.52 -4.61 -1.52
3 136 -6.11 -5.82 -4.76 -8.16 -3.24 -1.84 -1.59 -2.04 -6.81 -2.46 -11.48 -3.69 -0.17 -4.50 -1.22
P = 1.000 1.000 1.000 1.000 0.978 1.000 1.000 1.000 1.000 1.000 1.000 0.075 1.000 1.000 1.000
serous 169 -6.21 -5.82 -4.67 -8.17 -3.19 -1.86 -1.60 -2.17 -7.09 -2.46 -11.60 -3.50 -0.29 -4.50 -1.34
non-serous 22 -6.64 -5.50 -4.90 -8.11 -3.19 -1.29 -1.68 -1.53 -6.48 -2.34 -11.24 -3.37 -0.06 -4.48 -0.45
P = 1.000 1.000 1.000 1.000 0.999 0.168 1.000 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0.120
negative 90 -6.03 -5.75 -4.88 -8.17 -3.36 -1.71 -1.63 -1.75 -7.00 -1.96 -11.75 -3.38 0.06 -4.41 -0.98
positive 96 -6.37 -5.80 -4.43 -8.19 -3.05 -1.86 -1.55 -2.40 -7.00 -2.93 -11.40 -3.63 -0.52 -4.55 -1.37
P = 1.000 1.000 1.000 1.000 1.000 1.000 1.000 0.084 0.994 0.732 1.000 1.000 0.015 1.000 0.793
Table 4. Comparison§ of the mean log2(RQ) Values of SLCO and ABC Transporter Expression between clinicopathologic Parameters
§Relative to human qPCR reference RNA (Clontech); ♦analyzed using independent T-test; analyzed with one-sided ANOVA; Bold, statistically significant
Histology♦
Residual tumor load 
(5 missing)♦
Age (y)♦
FIGO (1 missing)
Grade (9 missing)
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P P
Age at diagnosis 1.01 (0.99 - 1.02) 0.267 ♦
Histology (non-serous v  serous) 0.95 (0.54 - 1.67) 0.864 ♦
FIGO stage 1.38 (1.08 - 1.76) 0.009 1.30 (1,03 - 1,64) 0.026
Grading 1.70 (1.14 - 2.54) 0.010 1.57 (1,06 - 2,32) 0.025
Residual disease (yes v no) 1.71 (1.12 - 2.47) 0.004 1.43 (0,96 - 2,12) 0.077
SLCO1A2 0.99 (0,94 - 1,04) 0.753 ♦
SLCO1B1 0.86 (0,73 - 1,01) 0.060 ∞
SLCO1B3 0.99 (0,95 - 1,04) 0.734 ♦
SLCO1C1 0.98 (0,84 - 1,15) 0.800 ♦
SLCO2A1 0.96 (0,83 - 1,11) 0.572 ♦
SLCO2B1 0.93 (0,78 - 1,11) 0.413 ∞
SLCO3A1 0.96 (0,78 - 1,18) 0.706 ♦
SLCO4A1 0.97 (0,87 - 1,08) 0.584 ♦
SLCO4C1 1.03 (0,97 - 1,10) 0.289 ♦
SLCO5A1 1.00 (0,95 - 1,05) 0.875 ♦
SLCO6A1 0.92 (0,83 - 1,02) 0.106 0.90 (0,81 - 1,00) 0.043
ABCB1 0.94 (0,81 - 1,09) 0.402 ∞
ABCB2 0.82 (0,71 - 0,94) 0.005 0.81 (0,70 - 0,93) 0.004
ABCC2 1.11 (0,94 - 1,23) 0.216 1.20 (1,01 - 1,42) 0.041
ABCC3 1.03 (0,90 - 1,17) 0.674 ♦
Table 5. Univariate and Multiple Cox Proportional Hazards Analysis
Relative risk(95% CI)‡
‡CI, confidence interval; categorical variable; ♦not implied for model building; ∞not selected in the 
backward selection procedure; bold, statistically significant.
Univariate
Disease free survival
Multiple
Relative risk(95% CI)‡
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